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Abstract 
 
Scientists thought of RNA as passive messenger molecules until the discovery of 
catalytic RNA (ribozymes) in the 1980s, which revolutionized thinking toward the 
multifaceted functions of RNA. The discovery of catalytic RNA also sparked an intense 
interest in exploring the catalytic functions of nucleic acids. As a close analog of RNA, 
the catalytic ability of DNA was evaluated and the first artificial DNA catalyst 
(deoxyribozyme) discovered in 1994. Since then, deoxyribozymes have been shown to 
catalyze a wide variety of chemical reactions, including phosphodiester bond cleavage, 
nucleic acid ligation, thymine dimer photoreversion, and the Diels-Alder reaction. 
However, the majority of deoxyribozyme-catalyzed reactions involve oligonucleotide 
substrates. To expand the scope of substrates that can be catalyzed by deoxyribozymes, 
the main theme of the thesis is to seek DNA catalysts that covalently modify the side 
chains of amino acids.  
The thesis describes the numerous selection efforts that led to the first discovery of a 
particular deoxyribozyme to catalyze the reactivity of a free tripeptide. This 
unprecedented discovery establishes a future potential use of DNA to modify proteins. In 
addition, this thesis presents the unexpected discovery of DNA-catalyzed reductive 
amination that may be applicable to site-specific labeling of nucleic acids. Finally, the 
thesis summarizes the optimization of the incubation conditions using click chemistry for 
direct free peptide selection. From these studies, we gained insights on how to direct our 
future selection efforts to identify DNA-catalyzed reactivity of amino acid side chains. 
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 1 
Chapter 1: Introduction 
1.1 Nucleic acids 
Nucleic acids, DNA and RNA, are important biological molecules. Most genomes are 
made up of DNA and a few viruses have RNA genomes. In an adult human, each of the 
~1013 somatic cells has its own DNA genome that comprises 46 chromosomes (~3.2 × 
109 base pairs). The DNA genetic material in chromosomes is transcribed to messenger 
RNA, which encodes information for protein translation. RNA has multiple biological 
roles beyond acting as a genetic material. The unexpected discovery of catalytic RNA by 
Thomas Cech and Sidney Altman in the 1980s revealed that RNA molecules can function 
as biocatalysts.1 Over the last two decades, the discoveries of RNA interference1 and 
regulatory RNA2 further illustrate the extensive biological role of RNA and intensify our 
ongoing research interest in nucleic acids. In addition, the powerful method of in vitro 
selection enables the identification of artificial functional nucleic acids.  
Chemical structure of nucleic acids. Nucleic acids are polymers of nucleotide 
monomers, connected by phosphodiester bonds. A nucleotide monomer is a phosphate 
ester of a pentose, which is covalently linked to a nitrogenous base at the C′1 position of 
the sugar. For a deoxyribonucleotide, it consists of DNA monomers in which the pentose 
is 2′-deoxy-D-ribose. For a ribonucleotide, the pentose is D-ribose. The nitrogenous 
bases are planar, heterocyclic derivatives of purine or pyrimidine. In nucleic acids, 
adenine and guanine are the purine bases; cytosine, thymine, and uracil (found in RNA) 
are the pyrimidine bases.  
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1.1.1 DNA structure and biological role 
Key features of B-form DNA double helical structure. The double helical structure 
was elucidated by Watson and Crick in 1953, which marked a new era of modern 
molecular biology.3 The Watson–Crick structure of B-DNA has several notable features. 
First, the two oligonucleotides are antiparallel with a right-handed twist to form a ~20 
Å diameter helix. A helical turn consists of 3.6 base pairs (bp). Second, each base is 
hydrogen bonding to a base on the opposite strand. These hydrogen bond interactions 
between the purine and pyrimidine base between the two strands of DNA, also known as 
complementary base pairings. The hydrogen bonds, ~1–10 kcal mol–1 in bond energy, are 
crucial in stabilizing the DNA double helix. The π–π stacking interaction, which arises 
from the hydrophobic interaction of the nucleobases, also assists the formation of the 
DNA double helix. Successful cooperative pairings of hydrogen bonding allow two DNA 
strands to assemble spontaneously into the double helical structure. Third, major grooves 
and minor grooves are observed on the surface spiraling along the helical axis. The major 
groove (11.7 Å in width, 8.8 Å in depth) is larger than the minor groove (5.7 Å in width, 
7.5 Å in depth). 
Other DNA structures. The A-form DNA is observed in a low humidity and high 
salt environment, whereas the B-form DNA is found in a high humidity and low salt 
environment. A-form DNA is shorter (11 bases in each turn of 28 Å, 2.6 bp per turn) than 
the B-form DNA. In A-form DNA, the 3′-carbon lies above the plane of the other four 
sugar carbons, which is known as C-3′ endo. In B-form DNA, the 2′-carbon is in the endo 
position (Fig 1.1).  
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Figure 1.1 The sugar puckering of DNA. (a) The C-3′ endo structure. (b) The C-2′ endo 
structure. 
 
Genes are made up of DNA. DNA is the building block of the genomes of almost all 
life forms, with the exception that some viruses have a RNA genome. A gene is a DNA 
sequence that encodes the information to produce proteins or functional RNA. In 
eukaryotes, genes consist of introns and exons. The chromosome consists of a collection 
of genes. The human genome (3.2 × 109 bp) locates in 22 different autosomes and 2 sex 
chromosomes in the nucleus. Genes are not evenly spaced in the chromosome. The 
average density of a human chromosome is between 0–64 genes per 100 kbp. 
DNA is tightly packed in a chromosome. In a chromosome, DNA is associated with 
DNA-binding histone proteins to form nucleosomes. The nucleosome contains eight 
histone proteins, two molecules each of H2A, H2B, H3 and H4. These eight proteins 
together form a barrel-shaped core octamer. 140–150 bp DNA wrap around the core 
octamer. The nucleosomes stack on top of each other to form a 30 nm fiber called 
chromatin.  
Only a fraction DNA encodes for functional units production. It was originally 
thought that the human genome contains around 80000–100000 genes. The completion of 
the Human Genome Project4 in 2003 revealed that the human genome contains around 
30000–40000 genes, which is only about twice the number of genes of a nematode worm 
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Caernoharbditis elegans. The exons of the human genome make up to 48 × 103 kbp, 
which is only 1.5% of the total genome. In contrast, 44% of the genome contains 
repetitive DNA sequences.  
The small number of genes in the human genome is explained by the diversification 
of the proteome by three processes as follows. First, at the mRNA level, a ribosome can 
bind to alternate promoter sequences upstream of mRNA to initiate translation, 
generating a few variants of gene products. Second, alternative splicing occurs in more 
than half of the RNAs in vertebrates. A particular mRNA is spliced in multiple ways, 
which results in distinct proteins after translation. Third, proteins can be covalently 
modified after translation, which is known as posttranslational modification. The use of 
alternate promoter sequences, alternative splicing, and posttranslational modifications 
increases the complexity of the human proteome. 
1.1.2 RNA structure and biological role 
Structural versatility of RNA. In biology, RNA are more structural versatile than 
DNA as they fold into different secondary structures such as bulges, hairpin loop and 
stem junction (Fig. 1.2). RNA also fold into complex tertiary structures for functions. For 
example, tRNA fold into three-dimensional structures with different functional domains.  
  
Figure 1.2 Examples of secondary structure of RNA. 
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RNA in protein translation. The series of contiguous triplet nucleotide mRNA 
codons encode the sequence of amino acids in a protein. In protein translation, the 
hydrogen bonding of the anticodon of a tRNA molecule and the codon of mRNA directs 
the addition of specific amino acids to the growing polypeptide in the ribosome.  
RNA in post-transcriptional regulation of gene expression 
Silencing RNA. In 1998, Andrew Fire and Craig Mellow observed that the injection of 
the double-stranded RNA duplex to Caenorthabditis elegans results in a twicking 
phenotype.1 This observation led to the discovery that the double-stranded RNA was 
responsible for gene silencing, known as RNA interference. In RNA interference, the 
enzyme DICER recognizes and cleaves invading double-stranded RNA viruses to ~ 20 nt 
small interference RNA (siRNA). SiRNA then associate with another protein RISC. 
RISC guides a specific siRNA to its complementary mRNA. The complementary base-
pairings leads to the degradation of the entire mRNA and hence represses the expression 
of a specific protein (Fig 1.3a). The discovery of RNAi greatly expedites the gene 
annotation process. Using RNAi, researchers can generate loss-of-function phenotypes 
within days.5 In comparison, it can take years to prepare knockout mice. Fire and Mellow 
were awarded the Nobel Prize in Physiology or Medicine in 2006 for their discovery. 
MicroRNA. In 1994, lin-4 microRNA2a (miRNA), a gene that regulates the timing of 
Caenorthabditis elegans larval development, was discovered by Victor Ambros and 
colleagues. miRNA are small ~ 22 nt non-coding RNA that post-transcriptionally repress 
protein expression by imperfect base-pairing of the mature miRNA with the 3′ UTR 
region of mRNAs. Numerous miRNA were identified in flies, worms, vertebrates and 
plants. miRNA are important regulators in developmental processes and are linked to 
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malignancy. More than 500 miRNA genes have currently been identified in humans and 
it was estimated that 30% of human genes are regulated by miRNA.6  
The process of miRNA maturation7 starts from the transcription of miRNA gene by 
RNA polymerase II in the nucleus to generate capped and polyadenylated transcripts 
called primary miRNA (pri-miRNA). (Fig 1.3b) The pri-miRNA are cleaved by RNase 
III endonuclease Drosha with its double-stranded RNA-binding protein cofactor Pasha 
(or DGCR8) to form ~70 nt stem loop precursor miRNA known as precursor miRNA 
(pre-miRNA). The stem loop pre-miRNA are actively exported by RAN–GTP and 
exportin 5 to the cytoplasm. In the cytoplasm, another RNase III endonuclease Dicer 
recognizes the double-stranded portion of the pre-miRNA and cleaves the pre-miRNA at 
about two helical turns away from the stem loop to generate transient ~22 nt 
miRNA:miRNA* duplexes. The miRNA:miRNA* duplexes are unwound and loaded into 
the Argonaute protein of the silencing complex (RISC) to yield ~22 nt mature miRNA. 
The miRNA are then hybridized to the 3′ UTR of the target mRNA by recognition 
through a 6 nt seeding region, which leads to transcription repression. 
RNA interference (RNAi) primarily silences protein expression through mRNA 
degradation. In contrast, miRNA, depending on the complementarity with 3′ UTR of the 
target transcript, work by either blocking the protein translation machinery or by mRNA 
degradation by similar mechanism as in RNAi.  
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Figure 1.3 The siRNA and miRNA biogenesis pathway. (a) The siRNA pathway. (b) The 
miRNA pathway.  
 
Riboswitches. Riboswitches are structural noncoding mRNA motifs that sense cellular 
metabolites and allosterically control gene expression.7 Each riboswitches contain an 
aptamer domain and an expression platform. The aptamer domain for a specific 
metabolite is well conserved, located upstream from the expression platform. 
Transcription termination, translation initiation and splicing control (only in eukaryotes) 
are the most common mechanisms utilized by riboswitches to regulate gene expression.7 
1.2 Ribozymes  
Ribozymes are single-stranded catalytic RNA molecules. The first two ribozymes 
were independently discovered by Thomas Cech and Sidney Altman in the 1980s.8 
Thomas Cech discovered that the ribosomal RNA of Tetrahymena Thermophila 
undergoes autocatalytic splicing of the introns and joining of the flaking extrons in the 
absence of protein. Sidney Altman discovered that the RNA component of Ribonuclease 
P (RNase P) is responsible of its ribonuclease activity in tRNA processing. Since then, 
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many natural ribozymes and artificial ribozymes were identified. Together, the growing 
repertoire of the reaction catalyzed by RNA molecules illustrates the catalytic ability of 
nucleic acids in general. In this section, natural ribozymes and artificial ribozymes will be 
discussed.  
1.2.1 Natural ribozymes 
Ribozymes can be found widely in nature such as in the genomes of viruses, fungi, 
and plants. The known natural ribozymes catalyze three types of reaction: 
transesterfication9-10, hydrolysis11 and amide bond formation12 (Fig 1.4). Examples of 
natural ribozymes are summarized in Table 1.1. 
 
 
Figure 1.4 Examples of reactions catalyzed by known ribozymes. (a) RNA cleavage by 
ribozyme-catalyzed tranesterification. (b) RNA cleavage by ribozyme-catalyzed hydrolysis. 
(c) Peptide bond formation catalyzed by rRNA in the ribosome. 
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Table 1.1 Examples of known natural ribozymes 
Ribozyme Size 
(nt) 
Function Reaction Products 
Self-Splicing 
RNAs 
    
Group I introns 200–
1500 
Splicing Transesterification 5′-guanosine 3′-OH 
introns, ligated exons 
Group II introns 300–
3000 
Splicing Transesterification 2′-5′ lariats and 3′-OH, 
ligated exons 
Self-cleaving 
RNAs 
   
 
Hammerhead 
ribozyme 
~40 Replication Transesterification 5′-OH, 2′,3-cyclic 
phosphate products 
Hairpin ribozyme ~60 Replication Transesterification 5′-OH, 2′,3′-cyclic 
phosphate products 
HDV ~80 Replication Transesterification 5-OH, 2′,3′-cyclic 
phosphate products 
RNase P 140–
490 
tRNA 
processing 
Hydrolysis 
5′-OH, 3′-OH products 
Peptidyl 
transferase 
RNAs 
   
 
Ribosomal RNA 
(23S E.coli rRNA, 
for example) 
 
~2900 
 
Peptidyl 
transfer 
Peptide bond 
formation 
A new peptide bond 
formation of the peptidyl-
tRNA at the A site, 
deacylated tRNA at the P 
site 
Adapted from Ref (13).  
 
Ribozyme-catalyzed transesterification. The majority of natural ribozymes 
catalyzes transesterfication. Self-cleaving hammerhead ribozymes, found in plant viroids 
and satellite RNA9, catalyze the site-specific cleavage of a phosphodiester bond by the 
nucleophilic attack of the 2′-hydroxyl of the ribose to the adjacent phosphodiester bond, 
and generate a 2′,3′-cyclic phosphate product and a 5′-hydroxyl product.  
In RNA splicing, the Group I and II introns catalyze two transesterfication reactions. 
Group I introns catalyzes the attack of an exogenous guanosine 3′-hydroxyl group to the 
5′ end of the intron (Fig 1.5a).10 In the subsequent transesterfication, 5′-exon is ligated to 
the 3′-introns. In Group II introns, the 2′-hydroxyl of branch-site adenosine attacks the 5′ 
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end of the intron followed by another transesterfication reaction to ligate the 5′-exon and 
the 3′-intron (Fig 1.5b). 
 
Figure 1.5 The Group I and II intron splicing pathway. (a) The Group I intron. (b) The Group 
II intron. 
 
Ribozyme-catalyzed hydrolysis. RNAse P, found in eukaryotes and prokaryotes, 
consists of a RNA component and at least one protein.11 In tRNA processing, RNase P 
catalyzes the cleavage of the 5′-end of pre-tRNA to generate the mature tRNA. The RNA 
component of the RNase P catalyzes the site-specific nucleophilic attack of a water 
molecule to a phosphodiester bond, which produces a 3′-hydroxyl and a 5′-phosphate 
product.  
Ribozyme-catalyzed peptide bond formation. One of the most important ribozyme-
catalyzed reactions is the peptide bond formation in the ribosome. The ribosome 
catalyzes the attack of the α-amino group of the aminoacyl-tRNA at the A site to the 
carbonyl carbon of the peptidyl-tRNA at the P site. The nucleophilic attack leads to a 
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single peptide bond formation of the peptidyl-tRNA at the A site and the deacylation of 
tRNA at the P site.  
In bacteria, the ribosome consists of three rRNA molecules and two subunits: 50S and 
30S. The peptidyl transferase center is located in the 50S subunit. Biochemical studies12 
provide evidence that the peptide bond formation is catalyzed by RNA. The notion of 
RNA-catalyzed peptide bond formation is further supported by the determination of high-
resolution X-ray crystal structures14 of the Haloarcula Marismortui ribosome with 
aminoacyl-tRNA substrate analogs (CCdA-phosphate-puromycin, and the mini-helix 3′ 
puromycin). The crystal structures show that the substrate analogs contact exclusively 
with the 23S rRNA in the peptidyl transferase center in the 50S subunit. The all-RNA 
active center establishes that 23S rRNA catalyzes the peptide bond formation while the 
protein components properly orient 23S rRNA for catalysis.  
1.2.2 Artificial ribozymes 
The discovery of natural ribozymes sparked an intense interest in identifying 
ribozyme in the laboratory. The method of in vitro selection enables researchers to 
identify many ribozymes that encompasses a wide range of reaction scopes.  
In vitro selection as a means to identify functional nucleic acids. In vitro selection 
is a powerful method that allows researchers to identify functional nucleic acids that are 
not found in nature.15 In vitro selection comprises iterative rounds of separation and 
amplification of the catalytically active functional nucleic acids. The separation method is 
either by size difference, affinity capture, or both. Polymerase chain reaction (PCR) is 
performed to amplify functional nucleic acids. The general processes of in vitro selection 
to identify artificial ribozymes and deoxyribozymes are similar. For ribozyme in vitro 
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selection, RT-PCR followed by transcription is required in the amplification step. 
Typically, nucleic acids with the desired catalytic function are selected from a pool of 
~1014 nucleic acid molecules. The nucleic acid molecules contain a random region 
flanked by constant sequences, which act as primer-binding regions for PCR 
amplification. Typically, the random region is 40–80 nt in size, denoted as N40–N80. The 
nucleic acid pool with a random region is physically ligated to one of its substrates. In the 
key selection step, the pool of nucleic acid is incubated with another substrate and 
divalent metal ions. Successful catalysis would result in either a size difference of the 
product and the substrate-ligated nucleic acid molecules which can be separated by gel 
purification, or incorporation of a chemical moiety that can be isolated by affinity 
capture. The isolated material contains a population of functional nucleic acids which is 
then PCR-amplified (for ribozyme in vitro selection, RT-PCR and transcriptions are 
performed at this stage), ligated to one of the substrates, and subjected to another 
selection step. These iterated rounds are continued to enrich the population of functional 
nucleic acids with the intended activity. 
Using in vitro selection, researchers are able to identify ribozymes with new catalytic 
functions beyond the typical natural ribozyme-catalyzed reactions such as 
transesterfication, hydrolysis and amide bond formation. The first artificial ribozymes 
were reported in 1990.16 Notably, artificial ribozymes can catalyze C–C bond formations 
such as in the aldol reaction17 (Fig 1.6a) and the Diels–Alder reaction18 (Fig 1.6b), which 
are considered the prototypical organic reactions. Table 1.2 exemplifies the wide scope 
of reactions that are catalyzed by ribozymes.  
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Figure 1.6 Examples of artificial ribozyme-catalyzed reaction. a) The aldol reaction. 17 b) 
The Diels-Alder reaction.18 
 
Table 1.2 Types of reactions catalyzed by artificial ribozymes 
Reaction Reference Reaction Reference 
RNA cleavage (19)  S-alkylation (20)  
RNA ligation (21)  Carbonate hydrolysis (22)  
RNA Phosphorylation (23)  Aldol reaction (17)  
RNA Branching (24)  Peptide bond formation (25)  
RNA Capping (26)  Amino acid adenylation (27)  
Mononucleotide polymerization (28)  Diels-Alder cycloaddition (18)  
Aminoacyl transfer (29)  Biphenyl isomerization (30)  
Aldehyde reduction (31)  Porphyrin metallation (32)  
Note: Adapted from (33). This table is not a comprehensive list of known ribozymes. 
 
Comparison of directed evolution and in vitro selection. Directed evolution is an 
in vitro method, useful for the development of highly active and specific biocatalysts, that 
shortens Darwinian evolution down to a period of months or even weeks.34 Directed 
evolution involves an iterative process that consists of mutant library generation, 
recombination, and screening or selection. The success of directed evolution to optimize 
catalyst activity is based on the efficiency and sensitivity of the screening or selection 
method, because mutant libraries can be generated by many methods, such as random 
mutagenesis by error-prone PCR, chemical mutagenesis and DNA shuffling.  
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There are several key differences between in vitro selection and directed evolution. 
(1) Directed evolution requires a known functional catalyst to begin the process. 
In directed evolution, a mutant library was generated from the wild-type to initiate the 
rounds of screening or selection. In contrast, in vitro selection of nucleic acid catalysts 
does not require prior knowledge of functional nucleic acid catalysts for a particular 
reaction. Directed evolution is very well suited for improving existing functions of 
proteins as well as functional nucleic acids. However, it is still a great challenge to 
identify new functions for protein catalysts without the amino acid sequence blueprints 
from known wild-type function protein catalysts.  
(2) Directed evolution comprising a screening or selection step followed by 
mutant library generation of the clones that exhibit desired activities. Therefore, directed 
evolution increases the diversity of the functional molecules throughout the round of 
screening or selections. Whereas, in the process of in vitro selection, the diversity of the 
nucleic acids molecules originated from the pool of the nucleic acids molecules in the 
beginning.  
In vitro selection is not amenable for de novo identification of new proteins. One of 
the obstacles is that amino acids monomers are not amenable for PCR amplification. The 
amplification obstacle can be overcome by the process of phage or mRNA display, which 
physically links the genetic information to the phenotype of the protein.  
However, more importantly, the 20 amino acids monomer makes up a vast collection 
of possible sequences that the sequence coverage of in vitro selection for protein is 
exceedingly low. For a small peptide of 100 amino acids in size, there are 20100 ~ 1 × 
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10130 possible amino acid sequences, which corresponds to the mass of 1.4 × 10134 
daltons.  
Screening and selection are distinct methods. Screening is the examination of 
catalytic activity by the phenotype of individual clones, typically by fluorescence and UV 
absorbance methods. In contrast, selection acts on a pool of genes such that only those 
that display the desired phenotype are propagated.35 Selection is the method of choice for 
larger libraries ≥107, because screening is applicable only to much smaller library sizes, 
typically only a few thousands clones (up to 106 library size).  
1.3 Deoxyribozymes 
Deoxyribozymes are single-stranded catalytic DNA molecules. Deoxyribozymes do 
not exist in nature and are identified by in vitro selection. The first deoxyribozyme was 
reported by Breaker and Joyce in 1994.36 The 10–23 and 8–17 deoxyribozyme37, reported 
by Santoro and Joyce, are the first examples of deoxyribozymes that have the ability to 
cleave all-RNA substrates (Fig 1.7). The 10–23 and 8–17 deoxyribozyme were named 
after the selection round and the clone number at which each of the deoxyribozyme was 
identified. The 10–23 deoxyribozyme cleaves all purine-pyrimidine junctions (robust 
activity at A↓U ; reduced activity at A↓C, and G↓C). The 8–17 deoxyribozyme cleaves at 
the A↓G junction. Variants of the 8–17 deoxyribozymes cleave all N↓G junctions, where 
N stands for any nucleotide.  
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Figure 1.7 RNA-Cleaving deoxyribozymes. (a) The 10–23 deoxyribozyme. (b) The 8–17 
deoxyribozyme. Adapted from Ref (37).  
 
Many deoxyribozymes have been identified after the first reported deoxyribozymes. 
Representative deoxyribozyme-catalyzed reactions include phosphodiester bond 
cleavage36 and ligation38,39, DNA depurination40, and Diels-Alder reaction41. Although 
nucleotides in DNA have less diverse functional groups than that of amino acids in 
protein, deoxyribozymes catalyze a wide variety of chemical reactions and display robust 
catalytic abilities with rate enhancement42 ranging from 103 to 1012. 
Table 1.3 Representative types of reactions catalyzed by deoxyribozymes 
Reaction  Reference Reaction Reference 
RNA cleavage (36)  DNA deglycosylation (43)  
RNA ligation (39)  Phosphoramidate Cleavage (44)  
RNA branching  (45)  Nucleopeptide linkage formation (46)  
RNA lariat formation (47)  Reductive Amination Chapter 3 
DNA phosphorylation (48)  Thymine dimer photoreversion (49)  
DNA adenylation (50)  DNA depurination (40)  
Oxidative DNA cleavage (51)  Diels-Alder cycloaddition (41)  
DNA hydrolysis (52)  Porphyrin metalation (53)  
Note: Adapted from (33). This table is not a comprehensive list of known deoxyribozymes. 
 
Practical applications of nucleic acid catalysts. Beyond fundamental studies of the 
catalytic potential of nucleic acids, researchers are applying deoxyribozymes and 
ribozymes for practical applications. 
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RNA-cleaving deoxyribozyme as alloteric biosensors. Metal ions or small molecules 
dependent RNA-cleaving deoxyribozymes can be utilized as sensors. The Lu laboratory 
reported several RNA-cleaving deoxyribozymes that sense specific metal ions. For 
instance, the 39E deoxyribozyme detects UO22+ at concentrations as low as 45 pM. 54 
The 39E deoxyribozyme cleaves a single ribonucleotide embedded in a DNA substrate 
with a fluorophore and a quencher at the 5′ end and 3′ end, respectively. Another 
quencher is covalently attached at the 3′ end of the 39E deoxyribozyme to suppress the 
fluorescence of the fluorophore. In presence of UO22+, the 39E deoxyribozyme cleaves 
at the ribonucleotide, which results in a fluorescence signal (Fig 1.8). 
 
Figure 1.8 The 39E deoxyribozyme senses uranium. Adapted from ref (38). 
 
Deoxyribozyme-catalyzed labeling of RNA. The Silverman laboratory has developed 
a RNA labeling approach, known as Deoxyribozyme-catalyzed Labeling (DECAL).55 
The 10DM24 deoxyribozyme catalyzes the nucleophilic attack of an internal 2′-hydroxyl 
of an adenosine of a specific RNA substrate to the α-phosphate of the 5′-triphosphate of 
another RNA substrate, which results in a branched RNA formation. In DECAL, a 5′-
triphosphate RNA is tagged with fluorophores or biotin molecules. The 10DM24 
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deoxyribozyme catalyzed the branched ligation of the tagged RNA to the internal 
adenosine. To demonstrate the applicability of the DECAL approach, specific sites of 
the P4–P6 domain of the group I introns were labeled with fluorophores using DECAL, 
which enables studies of the P4–P6 folding event using fluorescence resonance energy 
transfer (Fig 1.9). 
 
Figure 1.9 The DECAL approach to site-specifically label a RNA. Adapted from ref (37). 
 
1.4 Protein side chains modifications 
Protein side chains modifications are prevalent in biology. The importance of protein 
side chain modifications provides a scientific impetus for researchers to develop 
different in vitro methods to modify protein side chains. In the following section, protein 
side chains modifications in biology will be discussed briefly. 
Amino acids. Proteins are macromolecules made of amino acid monomers. The size 
range of proteins varies from about 70 amino acids to 15000 amino acids. Directed by its 
specific amino acid sequence, proteins are folded into three-dimensional structures that 
enable functions. There are 22 genetically encoded amino acids. The 21st amino acid, 
selenocysteine, is found in prokaryotes and eukaryotes (Fig 1.10a). The 22nd amino acid 
is pyrrolysine, found in an archaebacterium (Fig 1.10b).  
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Figure 1.10 The 21st and 22nd amino acid. (a) The selenocysteine side chain. (b) The 
pyrrolysine side chain. 
 
Figure 1.11 Posttranslational modifications of protein side chains. Adapted from Ref (56).  
 
In biology, the process of modifications of protein after translation is known as 
posttranslational modification (PTM; Fig 1.11). PTM is essential to almost all cellular 
processes. PTM is broadly divided in two categories: (1) the covalent addition of 
chemical moieties to amino acids side chains, (2) the proteolytic modifications of 
precursor proteins (for example, insulin is first translated to an inactive single-chain form 
followed by the cleavage by a specific protease into its active form).56 Table 1.4 
illustrates representaivte types of PTM. 
In general, PTM occurs at the nucleophilic amino acids side chains, in which 
enzymes catalyze the covalent addition of electrophilic chemical groups. Exceptions to 
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the rule that PTM occurs at the nucleophilic amino acids are exemplified as follows: (1) 
the hydroxylation of proline by reactive oxygen species that is mediated by Fe(II)-
dependent hydroxylases, and (2) the N-glycosylation at the low nucleophilic amide 
nitrogen of asparagines.56 
Table 1.4 Representative types of protein side chains modifications 
Residue Reaction Example 
Glu Methylation Chemotaxis receptor proteins 
Ser Phosphorylation Serine kinases and phosphatases 
 O-glycosylation Notch O-glycosylation 
Thr Phopshorylation Threonine kinases and phosphatases 
Tyr Phosphorylation Serine kinases and phosphatases 
 Sulfation CCR5 receptor maturation 
 Ortho-nitration Inflammatory responses 
His Aminocarboxypropylation Diphthamide formation 
 Phosphorylation Sensor protein kinases 
Lys N-methylation Histone methylation 
Cys S-Acylation Ras 
 Phosphorylation PTPases 
Met Oxidation to sulfoxide  Met sulfoxide reductase 
Arg N-ADP-ribosylation GSα 
Adapted from Ref (55).  
 
One important example PTM is the phosphorylation of the hydroxyl side chains of 
serine, threonine, and tyrosine by kinases, which are essential elements in modulating 
signaling cascades in cells. The majority of phosphorylation occurs at serine and 
threonine residues. Adenosine triphosphate is the major phosphoryl donor, in which the 
γ-phosphate is transferred to the hydroxyl side chains by kinases. In a small subset of 
kinases, guanosine triphosphate is the phosphoryl donor.  
The biological importance of kinases can be illustrated by the transmembrane 
receptor tyrosine kinases (RTK). The binding with ligands such as hormones and growth 
factors at the receptors at the extracellular region induces RTK to dimerize and 
autophorphorylate specific tyrosine residues in the cytosolic domain. The 
autophosphorylation concomitantly turns on a myriad of signaling cascades. For instance, 
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the Ras-activated MAP kinase cascade begins with the binding of its cognate growth 
factor at the RTK (Fig 1.12). The binding triggers the dimerization and 
autophosphorylation of tyrosine at the RTK. Grb2/Sem-5 binds to the phosphorylated 
tyrosine domain at the RTK and activates multiple downstream effectors such as Ras. 
Activated Ras binds to Raf, a Ser/Thr kinase that activates MEK. The MEK activates 
MAPK. MAPK activates several transcription factors. Given the prevalent examples and 
significance of side chain modifications in biology, novel methods to modify protein side 
chains are of great scientific interest. 
 
Figure 1.12 The Ras-activated MAP kinase cascade. Adapted from Ref (57). 
 
1.5 Thesis Research Focus 
 The Silverman laboratory first reported a deoxyribozyme that catalyzes a 
nucleopeptide ligation reaction using tyrosine hydroxyl as a nucleophile.46 The broad 
implication of this initial work is that nucleic acid catalysts have the ability to catalyze 
reactions involving protein side chains. This thesis reports the development of 
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deoxyribozymes that catalyze covalent modification of peptide substrates. Achieving this 
research objective will allow potential future DNA-catalyzed synthesis of biologically 
relevant protein variants.  
Chapter 2 details the comprehensive in vitro selection effort to identify novel 
deoxyribozymes that covalently modify the tyrosine or serine side chains of DNA-
tethered tripeptide substrates as well as the tyrosine side chain of a free tripeptide. 
Chapter 3 presents the unexpected discovery of DNA-catalyzed reductive amination that 
may be applicable to site-specific labeling of nucleic acids. Chapter 4 outlines the current 
efforts using click chemistry for direct free peptide selection. 
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Chapter 2: DNA-Catalyzed Covalent Modification of Amino Acid Side 
Chains in Tethered and Free Peptide Substratesa 
2.1  Introduction 
In this project, we performed a comprehensive in vitro selection study to identify 
deoxyribozymes that covalently modify amino acid side chains, with the long-term goal 
of achieving DNA-catalyzed covalent protein modifications. Using small-molecule 
reagents to covalently modify protein side chains is challenging because they are not site-
specific.1-3 On the other hand, engineering protein enzymes to obtain desired functions 
may be difficult.4 
In 2002, Baskerville and Bartel reported a ribozyme that catalyzes ligation of the N-
terminus of a polypeptide to the RNA.5 However, catalysis using potentially reactive 
amino acid side chains as nucleophiles has remained a challenge for nucleic acid 
catalysts. As a first step toward this goal, our laboratory has previously reported 
deoxyribozyme, Tyr16, which covalently modifies a tyrosine side chain to form a 
nucleopeptide linkage (Fig. 2.1). 
 
Figure 2.1 The Tyr1 deoxyribozyme catalyzes ligation of the tyrosine side chain to RNA. 
a The material described in this chapter has been published. 
Wong, O. Y.; Pradeepkumar, P. I; Silverman, S. K., DNA-Catalyzed Covalent Modification 
of Amino Acid Side Chains in Tethered and Free Peptide Substrates. Biochemistry 2011, 50, 
4741–4749. 
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Examples of covalent connections between the protein and RNA are found in 
biology, exemplified by the RNA genome of poliovirus, in which it is covalently linked 
to a viral protein.5-15 In order to achieve the proper orientation for catalysis, the Tyr1 
deoxyribozyme requires that the Tyr nucleophile to be embedded in two DNA 
oligonucleotide segments (Fig. 2.1). The broad implication of this result is that 
deoxyribozymes are able to use the side chain of an amino acid as a nucleophile. To 
circumvent this substrate requirement, this project sought deoxyribozymes that catalyze 
amino acid side chain reactivity in the context of a more open architecture, which 
requires that the deoxyribozyme simultaneously interact with and spatially organize the 
peptide substrate to achieve catalysis (Fig. 2.2). 
Figure 2.2 The selection efforts reported in this chapter sought deoxyribozymes that 
catalyze amino acid side chain reactivity in the context of a more open architecture. 
 
More importantly, such an open architecture could be amenable to catalytic function 
with large protein substrates. To expand the catalytic repertoire of deoxyribozymes, the 
Silverman laboratory is addressing the question of whether deoxyribozymes can achieve 
catalysis of all potential nucleophilic side chains of polypeptides. To answer this, we 
began with investigating the capability of deoxyribozymes in catalyzing reactions using 
tripeptide substrates. We performed selections using tripeptide substrates, Cys-Xaa-Ala, 
where Xaa denotes the potentially reactive amino acid Tyr, Ser, or Lys (Fig. 2.3). The 
nucleophile was presented with less preorganization by varying presentations of the 
tripeptide substrate to DNA in the open architecture. This chapter focuses on the in vitro 
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selection of deoxyribozymes that catalyze the ligation of the potentially reactive amino 
acid side chain in a tripeptide to the 5′-terminus of RNA in a non-preorganized format. 
2.2 Results and Discussion  
2.2.1 Selection experiments using tethered tripeptides (KC Selection) 
We began with selections using tripeptide substrates, Cys-Xaa-Ala, where Xaa 
denotes the potentially reactive amino acid Tyr, Ser, or Lys. Also, we include a negative 
control (Xaa = Ala, lacking any nucleophile). The substrates each had a short three-
carbon tether linking the 3′-terminal oxygen atom of the DNA anchor to the cysteine of 
the tripeptide via a disulfide bond, denoted DNA-C3-CXA (Fig. 2.3). Along with the 
negative control, we also include a positive control, called the dT selection (all DNA 
substrate, 3′-hydroxyl as the nucleophile). The DNA-C3-CXA conjugates were prepared 
by reaction with a DNA oligonucleotide with a 3′- terminal thiol and pyridyl disulfide 
activated Cys-Xaa-Ala substrates (Fig. 2.4, see Materials and Methods for preparation 
details).  
Figure 2.3 DNA-C3-Cys-Xaa-Ala substrates with Xaa = Ser, Tyr or Lys as the corresponding 
potential nucleophile. dT and Ala substrates were used as the positive and negative 
control selection, respectively. A 3′-tethered OH substrate was used as well. 
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Figure 2.4 DNA-Cys-Xaa-Ala conjugation reactions. The 3′-thiol modified DNA was first 
treated with DTT to produce a 3′-terminal thiol, followed by reaction with a pyridyl 
disulfide-activated Cys-Xaa-Ala. 
 
To initiate selections, a pool of N40 DNA was ligated to the 5′-triphosphate of the RNA 
substrates by T4 RNA ligase. In the key selection step, we incubated the DNA-tripeptide 
with the 5′-triphosphate of the RNA substrates in 50 mM HEPES, pH 7.5, 150 mM NaCl, 
2 mM KCl, 40 mM MgCl2, and 20 mM MnCl2 at 37 ºC for 2 h. The product was isolated 
by PAGE and subsequently amplified by PCR to go on to the next round. The amplified 
material containing deoxyribozymes with the intended catalytic activity was then ligated 
to the 5′-triphosphate of the RNA substrates. We performed the next selection step by 
incubating the ligated product with the DNA-tripeptide. The process was iterated for 
several rounds to enrich the population of deoxyribozymes with the ligation activity. 
2.2.2 KC selection progression 
For the dT positive control, we observed detectable DNA-catalyzed ligation between 
the 3′-OH and the 5′-triphosphate of the RNA in round 6. The pool activity of 
nucleopeptide-ligating deoxyribozymes was increased to 75% at round 11. The dT 
positive control validated the selection efforts were preformed properly. In the Cys-Tyr-
Ala selection, we first observed ligation activity in round 8. The ligation activity reached 
a plateau at 47% in round 10 (Fig. 2.5). To select for fast deoxyribozymes, we applied a 
time pressure in the selection step by lowering the incubation time from 2 h to 10 min. 
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However, after three rounds at increased time pressure, the activity was not increased. No 
activity was observed for the Cys-Ser-Ala, Cys-Lys-Ala, or 3′-tethered OH selections. 
 
 
Figure 2.5 KC selection progression. (A) 8% PAGE image of key rounds for the individual 
selection experiments with DNA-tripeptide substrates. The open triangle marks the DNA-
tripeptide substrate, and the filled triangle marks the ligation product. (B) Selection 
progression.  
 
2.2.3 Cloning and sequencing of KC deoxyribozymes 
We surveyed the clones of the DNA-C3-CYA selection in round 10 when activity was 
the most robust. Of the 24 clones surveyed, 22 showed catalytic activity in a trimolecular 
format, in which the DNA-C3-CXA and 5′-triphophate RNA were not connected to the 
DNA enzyme. Fig. 2.6 shows the results from the kinetic screening. We designated KC 
to represent the DNA-C3-CYA selection. Individual deoxyribozymes from round 10 of 
the KC pool were cloned. 
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Figure 2.6 Kinetic screening of individual KC clones. Reaction conditions: 50 mM HEPES, 
pH 7.5, 150 mM NaCl, 2 mM KCl, 40 mM MgCl2, and 20 mM MnCl2 at 37 ºC. Time point: 30 s, 
45 min, 90 min. From the results of this assay, 10KC clones 3, 6, 8, 9, 10, 17, 19, 23, 31 
were chosen for sequencing.  
 
Figure 2.7 Sequence alignment of 10KC sequences. A single dominant sequence, 10KC3, 
was identified. 
 
Sequences were obtained for 10 of the active clones. The 10 sequences were in 
consensus, except two transitions at position 10 and 14 were observed (Fig. 2.7). It is 
likely that the transitions were non-essential to the catalytic activity. Thus, we obtained a 
single sequence 10KC3 (5′-CAAGGAGCGTTGGACAAGCGCGGGTCGTTCCAAAAGTAGG-3′) for a 
detailed characterization. 
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To investigate the capability of the 10KC3 deoxyribozyme to use the Cys-Tyr-Ala 
(CYA) substrate remotely placed from the anchor DNA, we assayed the 10KC3 
deoxyribozyme in three different formats: C3-tethered, HEG-tethered, and untethered 
CYA (Fig. 2.8). The three formats present the Tyr nucleophile in different spatial 
orientations. In the HEG-tethered format, we placed a hexa(ethylene glycol) (HEG) 
linker between the tripeptide and the anchor DNA (DNA-HEG-CYA). To prepare DNA-
HEG-CYA, hexa(ethylene glycol) spacer phosphoramidite was first coupled to the 3′-
thiol modifier solid support during solid-phase synthesis. After the solid-phase synthesis, 
DNA-HEG with a 3′-thiol modifier was reduced and coupled to the PyS-S-Cys-Tyr-Ala 
to yield a DNA-HEG-Cys-Tyr-Ala conjugate (see Materials and Methods for details). We 
tested the DNA-HEG-Cys-Tyr-Ala as a substrate for the 10KC3 catalysis. 10KC3 was 
able to catalyze the ligation of the DNA-HEG-Cys-Tyr-Ala and the 5′-triphosphate of the 
RNA (Fig. 2.8B). In the untethered CYA format, the CYA is not linked to the DNA 
anchor, and the cysteine thiol function group is terminated with a tert-butyl disulfide 
(Fig. 2.8C).  
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Figure 2.8 Various spatial presentations of the Tyr nucleophile. (A) In DNA-C3-tethered 
substrates, the tripeptide was connected to the DNA anchor via a propyl linker. (B) In DNA-
HEG-tethered substrates, the tripeptide was covalently attached to the DNA anchor with a 
hexa(ethylene glycol) linker. (C) In free CYA substrates, the cysteine thiol moiety was 
terminated with tert-butyl disulfide.  
 
10KC3 showed excellent reactivity toward C3-tethered and HEG-tethered CYA 
substrates with 70% yield (kobs = 0.30 h–1) and 62% (kobs = 0.10 h–1) yield in 60 h, 
respectively. However, 10KC3 displayed modest activity toward the free CYA substrates 
with ~10% yield at 60 h (kobs = 0.0017 h–1, linear fit; Fig. 2.9). 
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Figure 2.9 Kinetic assay of the 10KC3 deoxyribozyme. (A) 8% PAGE image of kinetic assay 
with DNA-C3-CYA, DNA-HEG-CYA, and free CYA. Time points were taken at 30 s, 10 min, 2 
h, 10 h and 60 h. (B) Kinetic plot of the data from panel A. The data was fitted using first-
order kinetics, i.e. yield = Y•(1 – e–kt), where k = kobs. See Materials and Methods for kinetic 
assay procedures.  
 
Despite the low overall yield of covalently modification of free CYA catalyzed by the 
10KC3 deoxyribozyme, the results demonstrate that deoxyribozymes can use peptide 
substrates that are placed remotely away from the anchor DNA. Therefore, further 
optimization of 10KC3 and new selection designs are required to achieve activity toward 
free CYA. 
2.2.4 Follow-up selection with the 10KC3 25% partially randomized pool using 
DNA-C3-CYA (NG selection) 
The identification of 10KC3 established the potential of deoxyribozymes to catalyze 
covalent modification of the Tyr hydroxyl of a free CYA substrate. The initial KC 
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selection effort covered only 10–10 sequence space (we started with a pool of 1014 
deoxyribozyme out of 1024 possible sequences). We reasoned that by exploring the 
sequence space that is closely related to the original 10KC3 sequence would allow us to 
obtain deoxyribozymes that displayed improved activity toward the free CYA substrate. 
To explore sequence space that is closely related to the 10KC3 deoxyribozyme, we 
designed a selection with DNA-C3-CYA substrate using the DNA pool with the enzyme 
region partially randomized to the extent of 25% per nucleotide position (i.e., 75% related 
to the original 10KC3 sequence). The average number of mutations was 10 out of 40 
nucleotides as a result of the partial randomization. We denoted the selection effort using 
the 25% partially randomized pool from the 10KC3 sequence as the NG selection.  
2.2.5 NG Selection progression  
We observed a detectable activity with the RNA substrate in round 2 with 2% yield. 
The pool activity of nucleopeptide-ligating deoxyribozymes was increased to 57% in 
round 6 (Fig. 2.10). To select for faster deoxyribozymes, we applied a time pressure in 
the selection step by lowering the incubation time from 2 h to 10 min in round 7. 
However, after four rounds at increased time pressure, no enrichment was observed as the 
activity remained at ~26%. We applied an additional time pressure by decreasing the 
incubation time from 10 min to 1 min starting at round 9 and observed 5% activity. We 
continued the selection with 1 min incubation for an additional round and observed no 
enrichment of activity (8 %). The pool of deoxyribozymes was cloned and sequenced at 
round 9 with 1 min incubation. 
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Figure 2.10 NG selection progression. The NG selection was initiated with the 10KC3 25% 
partially randomized pool using the DNA-C3-CYA substrate. Reaction conditions: 50 mM 
HEPES, pH 7.5, 150 mM NaCl, 2 mM KCl, 40 mM MgCl2, and 20 mM MnCl2 at 37 ºC. To 
identify fast deoxyribozymes, a time pressure was applied. Beginning in round 6, the 
reaction was incubated at 10 min instead of the default 2 h incubation. In addition, the 
effect of the timing for applying the time pressure was studied. We compared the effect of 
applying the time pressure from 10 min to 1 min starting in round 8 or in round 9. It was 
found that applying the time pressure at different rounds in a rather late stage of selection 
yielded comparable results. After round 9 at 1 min incubation, the pool of deoxyribozymes 
was cloned and sequenced. The blue asterisk marks the round and activity where the NG 
selection was cloned and sequenced.  
 
2.2.6 Cloning and sequencing of NG deoxyribozymes 
Out of all the 22 clones surveyed (Fig. 2.11), 11 of the clones were sequenced. From 
the sequence alignment, three conserve motifs were observed (Fig. 2.12).We synthesized 
six sequences (9NG2, 3, 5, 6, 14, 15) for further kinetic studies. 
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Figure 2.11 Kinetic screening of individuals 9NG clones. Reaction conditions: 50 mM 
HEPES, pH 7.5, 150 mM NaCl, 2 mM KCl, 40 mM MgCl2, and 20 mM MnCl2 at 37 ºC. Time 
points: 30 s, 5 min, 20 min, 50 min. From the results of this assay, 9NG clones 2, 3, 5, 6, 10, 
11, 12, 14, 15, 20, 21 were chosen for sequencing. The asterisks highlight the clones that 
were chosen for sequencing.  
 
Figure 2.12 Sequence alignment of 9NG sequences. Highlighted sequences were 
synthesized by DNA solid-phase synthesis for kinetic characterizations. 9NG14, 
highlighted by an asterisk, was a representative deoxyribozyme from the 9NG selection 
effort. 
 
9NG14, a representative deoxyribozymes identified in the NG selection, showed 
excellent reactivity toward C3-tethered and HEG-tethered CYA substrates with 77% yield 
(kobs = 5.6 h–1) and 75% yield (kobs = 1.6 h–1), respectively. 9NG14 displayed a 20-fold 
increase in kobs with the C3-tethered substrates compared to the 10KC3 deoxyribozyme. 
For the HEG-tethered, a 16-fold increase in kobs compared to the 10KC3 deoxyribozyme 
that was observed. 9NG14 was not selected to work with the free CYA substrate yet 
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9NG14 showed great improvement toward the free CYA with 40% yield in 60 h (kobs = 
0.063 h–1, t 1/2 of 11h, ~30-fold faster and with a 4-fold improvement in yield compared 
to 10KC3(Fig. 2.13). Five other deoxyribozymes were also studied (9NG2, 3, 5, 6, 
15).They displayed similar kinetic profiles as 9NG14. 
 
Figure 2.13 Kinetic assays of 9NG deoxyribozymes. (A) Kinetic plot of 9NG14, one of the 
representative deoxyribozymes from the NG selection. (B) Kinetic plot of 9NG2, 3 and 6. 
The data was fitted using the first-order kinetics equation. 9NG5 and 15 also showed 
similar activities (data not shown).  
 
2.2.7 Selection with DNA-HEG-CYA (MN selection) and selection progression 
We performed selection with DNA-HEG-CYA using unbiased N40 pool, denoted as 
the MN selection. The HEG tether is longer than the C3 tether. Therefore, the HEG 
tethered substrate imposes a more spatially challenging requirement for the 
deoxyribozymes to achieve catalysis compared to the C3 tethered-substrates. We 
expected that the deoxyribozymes from the new DNA-HEG-CYA selection effort would 
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yield deoxyribozymes that function better with free CYA substrate than from the KC 
selection effort.  
The MN selection first showed discernable activity in round 7 and the activity was 
increased to 38% at round 10 and reached its plateau in round 11 (46%). To select for fast 
enzymes, we applied a 10 min incubation time pressure starting in round 12 (Fig. 2.14). 
However, with the applied time pressure for three addition rounds, the activity remained 
at ~12%. The deoxyribozymes from the MN pool in round 11 with 2 h incubation were 
cloned. 
 
Figure 2.14 MN selection progression. The MN selection was initiated with the unbiased 
N40 pool using the DNA-HEG-CYA substrate. Reaction conditions: 50 mM HEPES, pH 7.5, 
150 mM NaCl, 2 mM KCl, 40 mM MgCl2, and 20 mM MnCl2 at 37 ºC. To identify fast 
deoxyribozymes, time pressure was applied. Starting from round 12, the reaction was 
incubated at 10 min instead of the default 2 h incubation. Three additional selection 
rounds with the applied time pressure did not enrich activity. After round 11 with 2 h 
incubation, deoxyribozymes were cloned and sequenced. The blue asterisk denotes the 
round and activity where the deoxyribozymes were cloned and sequenced.  
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2.2.8 Cloning and sequencing of MN deoxyribozymes and their kinetics 
Round 11 of the MN selection was cloned. We surveyed 11 clones and 9 of them 
were active without including two clones which had less than 6% activity (Fig. 2.15). Of 
the 9 actives clones, 6 of the clones were sequenced (Fig. 2.16). 11MN5, a representative 
deoxyribozymes identified in the NG selection, showed excellent reactivity toward C3-
tethered and HEG-tethered CYA substrates with 77% yield (kobs = 3.1 h–1) and 76% yield 
(kobs = 0.86 h–1), respectively. 11MN5 displayed a 20-fold increase in kobs with the C3-
tethered substrates compared to the 10KC3 parent. For the HEG-tethered, a 16-fold 
increase in kobs compared to the 10KC3 deoxyribozyme was observed. 11MN5 was not 
selected to work with the free CYA substrate. Remarkably, 11MN5 showed a significant 
improvement toward the free CYA with 55% yield in 60 h (kobs = 0.05 h–1, t 1/2 of 14 h, 
~30-fold faster and 5 fold improvement in yield compared to 10KC3, Fig. 2.17A). Two 
other deoxyribozymes were also studied (11MN10, 11MN19).They displayed similar 
kinetic profiles as that of 11MN5 (Fig. 2.17B). 
 
Figure 2.15 Kinetic screening of individual 11MN clones. Reaction conditions: 50 mM 
HEPES, pH 7.5, 150 mM NaCl, 2 mM KCl, 40 mM MgCl2, and 20 mM MnCl2 at 37 ºC. Time 
points: 30 s, 45 min, 90 min. From the results of this assay, 11MN clones 4, 5, 7, 8, 9, 10, 
12, 17, 19, 20, 21 were chosen for sequencing. The asterisks highlight the clones that were 
chosen for sequencing. 
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Figure 2.16 Sequence alignment of 11MN sequences. Highlighted sequences were 
prepared by solid-phase synthesis for kinetic characterization. 11MN5, marked by an 
asterisk, was a representative deoxyribozyme from the MN selection effort. 
 
 
Figure 2.17 Kinetic assays of 11MN deoxyribozymes. (A) Kinetic plot of 11MN5. 11MN5 was 
one of the representative deoxyribozymes from the MN selection. (B) Kinetic plot of 
11MN10 and 11MN19. The kinetic profile of 11MN10 was as follows: with C3-tethered CYA 
(73%, kobs = 0.81 h–1), HEG-tethered CYA (73%, kobs= 0.81 h–1), free CYA (32%, kobs = 0.044 
h–1). The kinetic profile of 11MN19 was as follows: with C3-tethered CYA (80%), HEG-
tethered CYA (80%, kobs = 0.73 h–1), free CYA (35%, kobs = 0.032 h–1). 
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2.2.9 Selection using DNA-HEG-CYA (MP selection, redirection from 4KC)  
 
We performed a selection with DNA-HEG-CYA by redirecting from the round 4 of 
the KC selection, denoted as the MP selection. In the MP selection, we started with the 
pool of uncloned deoxyribozymes from the round 4 of the DNA-C3-CYA (KC) selection, 
and redirected the pool to catalyze reaction involving the DNA-HEG-CYA substrate. As 
part of the comprehensive effort to study the optimal strategy of in vitro selection for 
DNA–catalyzed covalent modification of free CYA, we reasoned that the redirection 
using the 4KC pool with HEG-tethered CYA could yield deoxyribozymes that function 
better with free CYA. Second, the MP selection effort would provide us insights on 
whether redirection is a viable strategy for future selection efforts.  
Fig. 2.18 depicts the MP selection progression. The MP selection first showed 
detectable activity at round 8 and the activity was increased to 23% in round 11 and 
reached its plateau in round 12 (36%). A 10 min incubation time pressure was applied 
starting in round 12. However, with the applied time pressure for three additional rounds, 
the activity remained at ~11%. The MP pool in round 12 with 2 h incubation (36% 
activity) was cloned. 
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Figure 2.18 MP selection progression. The MP selection was initiated with 4KC pool using 
the DNA-HEG-CYA substrate. Reaction conditions: 50 mM HEPES, pH 7.5, 150 mM NaCl, 2 
mM KCl, 40 mM MgCl2, and 20 mM MnCl2 at 37 ºC. To identify fast deoxyribozymes, a time 
pressure was applied. Starting in round 12, the reaction was incubated at 10 min instead of 
the default 2 h incubation. Three additional selection rounds with the applied time 
pressure did not enrich activity. In round 12 with 2 h incubation, deoxyribozymes were 
cloned and sequenced. The blue asterisk denotes the round and activity (36%) where 
deoxyribozymes were cloned and sequenced.  
 
2.2.10 Cloning and sequencing of MP deoxyribozymes and their kinetics 
Of the 13 clones surveyed, 12 of them were active (Fig. 2.19). Sequences were 
obtained for 10 of the active clones (Fig. 2. 20). Comparison of the MP sequences reveals 
that 12MP4, 8, 16, and 20 are identical. Also, 12MP5, 19, 17 are identical. 12MP5 and 
12MP10 differ by one nucleotide; 12MP5 and 12MP15 also differ by one single 
nucleotide. 12MP4, 12MP9 (identical to 12MP5), and 12MP11 were prepared by solid-
phase synthesis for further kinetic analyses. 
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Figure 2.19 Kinetic screening of individuals 12MP clones. Reaction conditions: 50 mM 
HEPES, pH 7.5, 150 mM NaCl, 2 mM KCl, 40 mM MgCl2, and 20 mM MnCl2 at 37 ºC. Time 
points: 30 s, 45 min, 90 min. From the results of this assay, all of the 12 were chosen for 
sequencing. The black circles denote identical sequences (12MP4, 8, 16, 20). The red 
rectangles also mark identical sequences (12MP5, 9, and 17).  
 
Figure 2.20 Sequence alignment of 12MP sequences. Highlighted sequences were 
prepared by solid-phase synthesis for kinetic characterization.  
 
The activity of 12MP4, 12MP9, and 12MP11 were assayed with DNA-HEG-CYA. 
12MP4, 12MP9 and 12MP11 showed excellent reactivity with the parent DNA-HEG-
CYA substrate in 24 h incubation with 70% yield (kobs =1.6 h–1), 86% yield (kobs = 0.44 h–
1) and 91% (kobs = 0.66 h–1), respectively (Fig. 2.21). Their activities toward free CYA 
were also assayed. 12MP4, 12MP9, 12MP11 catalyze the free CYA reactivity with 40% 
yield, 29% yield, and 34% yield, respectively. The detailed kinetic profile of 12MP4, 9 
and 11 were not determined. Compared to the 10KC3 deoxyribozyme, 12MP4 was 16-
fold faster; 12MP9 was 4-fold faster and 12MP11 showed 7-fold improvement in rate 
compared to the 10KC3 deoxyribozyme. From these kinetic data, 12MP deoxyribozymes 
showed a comparable rate and yield as the 11MN5 deoxyribozyme. 
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Figure 2.21 Kinetic assays of 12MP deoxyribozymes. 12MP4, 12MP9, 12MP11 were 
assayed with the parent substrate DNA-HEG-CYA. The data was fitted using first-order 
kinetics.  
 
2.2.11 Reselection using DNA-HEG-CYA (MQ selection, partially 25% randomized 
10KC3)  
We performed reselection with DNA-HEG-CYA from the partially randomized 
10KC3 pool, denoted as the MQ selection. We expected that the reselection using the 
partially randomized 10KC3 pool with HEG-tethered CYA would yield deoxyribozymes 
that function well with free CYA. The MQ selection first showed detectable activity in 
round 2 and the activity was increased to 29% in round 5 and reaches its plateau in round 
7 (47%). To select for fast enzymes, we applied a 10 min incubation time pressure 
starting in round 8 (Fig. 2.22). However, with the applied time pressure for three addition 
rounds, the activity remained at ~14%. The deoxyribozymes from the MP pool in round 8 
with 10 min incubation (13% activity) were cloned. 
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Figure 2.22 MQ selection progression. The MQ selection was initiated with the 25% 10KC3 
partially randomized pool using the DNA-HEG-CYA substrate. Reaction conditions: 50 mM 
HEPES, pH 7.5, 150 mM NaCl, 2 mM KCl, 40 mM MgCl2, and 20 mM MnCl2 at 37 ºC. To 
identify fast deoxyribozymes, time pressure was applied. Starting at round 8, the reaction 
was incubated at 10 min instead of the default 2 h incubation. Three additional selection 
rounds with the applied time pressure did not enrich activity. The pool of deoxyribozymes 
was cloned and sequenced at round 8. The blue asterisk denotes the round and activity 
(13%) where the MQ selection was cloned and sequenced. 
 
2.2.12 Cloning and sequencing of MQ deoxyribozymes and their kinetics 
Of the 15 clones surveyed, 13 of them were active (Fig. 2.23). Sequences were 
obtained for seven of the clones. 8MQ5, 8MQ7, and 8MQ11 were prepared by DNA 
solid-phase synthesis for further kinetic analyses (Fig. 2.24). The activity of 8MQ5, 
8MQ7, and 8MQ11 were assayed with DNA-HEG-CYA. 8MQ5, 8MQ7, and 8MQ11 
show excellent reactivity with the parent DNA-HEG-CYA substrate after 24 h incubation 
with 79% yield (kobs = 0.20 h–1), 72% yield (kobs = 0.72 h–1) and 76% (kobs = 0.37 h–1), 
respectively (Fig. 2.25). Their activities toward free CYA were also studied. 8MQ5, 
8MQ7, and 8MQ11 catalyzed the free CYA reactivity in 60 h incubation with 36% yield, 
41% yield, and 21% yield, respectively. Their detailed kinetic profiles were not 
determined. Compared to the 10KC3 deoxyribozyme, 8MQ5 reacted with HEG-CYA at a 
similar rate; 8MQ7 was 7-fold faster and 8MQ11 showed 4-fold improvement in rate 
 49 
compared to the 10KC3 deoxyribozyme. From these kinetic data, 8MQ deoxyribozymes 
show comparable rate and yield as the 11MN5 deoxyribozyme. 
 
Figure 2.23 Kinetic screening of individual 8MQ clones. Reaction conditions: 50 mM 
HEPES, pH 7.5, 150 mM NaCl, 2 mM KCl, 40 mM MgCl2, and 20 mM MnCl2 at 37 ºC. Time 
point: 30 s, 45 min, 90 min. Sequences were obtained and highlighted by the asterisks. 
 
Figure 2.24 Sequence alignment of 8MQ sequences. Highlighted sequences were prepared 
by solid-phase synthesis for kinetic characterization.  
 
Figure 2.25 Kinetic assays of 8MQ deoxyribozymes. 8MQ5, 8MQ7 and 8MQ11 were 
assayed with the parent substrate DNA-HEG-CYA. The data was fitted using first-order 
kinetics.  
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2.2.13 Seeking serine reactivity: alternative selection approach with a tethered 
hydroxyl substrate (MY to MZ selection) and selection progression 
All of the previous experiments have shown promising DNA-catalyzed reactivity 
toward the Tyr side-chain. Previous results from this laboratory have also demonstrated 
that the Ser side chain is much more challenging than analogous reactivity of Tyr, even in 
a highly preorganized architecture. Because the selection effort with the DNA-C3-CSA 
substrate gave no activity, we pursued an alternative approach. We initiated a selection 
effort with a DNA substrate conjugated at its 3′-terminus to a tri(ethylene glycol) (TEG) 
tether that terminates in an aliphatic hydroxyl group (DNA-TEG-OH). Upon seeing 
activity with the DNA-TEG-OH, we redirected the selection with we redirected the 
selection effort using DNA-C3-CSA as a substrate (Fig. 2.26). 
 
Figure 2.26 Alternate approach to obtain DNA-catalyzed serine modification. The selection 
effort was initiated first with a DNA substrate conjugated with an aliphatic hydroxyl group 
(DNA-TEG-OH) and redirected with the DNA-C3-CSA substrate. 
 
2.2.14 Cloning and sequencing of MZ deoxyribozymes and their kinetics 
We observed DNA-catalyzed ligation between the DNA-TEG-OH with the RNA in 
round 11 with 8% yield. We redirected the selection effort using DNA-C3-CSA from the 
round 11 pool. The pool’s ligation activity was 6% at round 15, where individual 
deoxyribozymes were identified by cloning (Fig. 2.27). 
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Figure 2.27 MY and MZ selection progression. The MY selection was initiated with the N40 
pool using the DNA-TEG-OH substrate. Reaction conditions: 50 mM HEPES, pH 7.5, 150 
mM NaCl, 2 mM KCl, 40 mM MgCl2, and 20 mM MnCl2 at 37 ºC. The selection effort was 
redirected with DNA-C3-CSA starting in round 12, denoted as the MZ selection. The pool of 
MZ deoxyribozymes was cloned and sequenced at round 15. The blue asterisk denotes the 
round and activity (6%) where the MZ selection was cloned. 
 
Figure 2.28 Representative kinetic screening of individual 15MZ clones. Only fraction of 
the clones assayed was presented here. The grey color scheme was used because clones 
contain double-inserts were also assayed. Reaction conditions: 50 mM HEPES, pH 7.5, 150 
mM NaCl, 2 mM KCl, 40 mM MgCl2, and 20 mM MnCl2 at 37 ºC. Time points: 30 s, 45 min, 90 
min. Sequences were obtained and highlighted by the asterisks. 
 
Deoxyribozymes in round 15 of the 15MZ selection were cloned. Of the 56 clones 
surveyed, the majority of the clones (36 clones) contain two of the N40 sequences (double 
insert), as a result of two sequences that were ligated to the plasmid during cloning. Only 
5 out of the 20 of the clones with the corrected insert were active. The number of the 
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correct insert clones was low therefore we also surveyed the clones with double insert 
(Fig. 2.28). 
 
 
Figure 2.29 Kinetic assays of the 15MZ36 deoxyribozyme. (A) PAGE image for assays with 
the three CYA substrates. Time points were taken at t = 30 s, 10 min, 2, 10 and 60 h. (B) 
PAGE image for reaction of the three analogous CSA substrates. (C) Kinetic plots for data 
from panels A and B. 
 
The best deoxyribozyme that identified from this effort 15MZ36, had kobs = 0.52 h–1 
and 62% yield after 60 h incubation with the DNA-C3-CSA substrate. However, 15MZ36 
had only around 6% yield after 60 h incubation with the DNA-HEG-CSA substrate and 
no detectable activity with free CSA. The three analogous CYA substrates reactivity were 
assayed with 15MZ36 (Fig. 2.29). 15MZ36 displayed robust activities with the tethered 
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variants. For DNA-C3-CSA, 15MZ36 had kobs = 80 h–1 and 82% yield after 60 h 
incubation (~270-fold faster than 10KC3, and ~26-fold faster than 11MN5). For DNA-
HEG-CYA, 15MZ36 had kobs = 18.7 h–1 and 81% yield after 60 h incubation (~ 60-fold 
faster than 10KC3, and ~22-fold faster than 11MN5). For free CYA, 15MZ36 had kobs = 
0.5 h–1 and 50% yield after 60 h incubation (~290-fold faster than 10KC3, and 10-fold 
faster than 11MN5). As negative controls, no reactions with DNA-C3-CAA and free 
CAA were observed.  
Two other deoxyribozymes, 15MZ30 and 15MZ49 were also assayed to assess the 
improvement in reactivity compared to 15MZ36 (Fig. 2.30). For simplicity, three 
illustrative substrates CYA, DNA-C3-CSA and DNA HEG-CSA were used for the 
assays. 15MZ30 and 15MZ49 were not faster than 15MZ36. 
 
Figure 2.30 Kinetic plots of the 15MZ30 and 15MZ49 deoxyribozyme. 
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2.2.15 Reselection using DNA-C3-CYA  
(QG selection, partially 25% randomized 15MZ36) 
15MZ36 had robust activity toward all the Tyr variants and the tethered Ser variants 
but not with the free CSA substrate. To select for free CSA reactivity, we designed a new 
selection, aiming to explore sequences closely related to 15MZ36. We initiated a 
selection effort using the partially (25%) randomized 15MZ36 with DNA-C3-CYA, 
denoted as the QG selection. We anticipated that the QG selection would allow us to 
obtain deoxyribozymes with improved reactivity with free CYA and CSA.  
In the QG selection effort, we also applied a time pressure and redirected the 
selection using the DNA-HEG-CYA substrate. However, the redirection with DNA-
HEG-CYA was not fruitful as only 1% activity was detected. The deoxyribozymes in the 
QG selection with DNA-C3-CYA substrate in round 6 with 10 min incubation (13%) 
were cloned (Fig. 2.31). 
 
Figure 2.31 QG selection progression. The QG selection was initiated with 15MZ36 partially 
(25%) randomized pool using the DNA-C3-OH substrate. Reaction conditions: 50 mM 
HEPES, pH 7.5, 150 mM NaCl, 2 mM KCl, 40 mM MgCl2, and 20 mM MnCl2 at 37 ºC. To 
select for faster deoxyribozymes, 10 min and 1 min incubation time pressures were 
applied. To select for deoxyribozyme that can function better with free CYA, the selection 
effort was redirected with DNA-HEG-CYA starting in round 12, denoted as 6QG (HEG). The 
pool of QG deoxyribozymes was cloned and sequenced at round 6. The red box highlights 
the round and activity (13%) where the QG selection was cloned. 
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2.2.16 Cloning and sequencing of QG deoxyribozymes and their kinetics 
6QG clones were assayed with the parent DNA-C3-CYA substrate and all 14 clones 
were active (Fig. 2.32). Sequences were obtained for all of the clones (Fig. 2.33). The 
kinetic characteristics of 6QG deoxyribozymes were studied to compare with the 
15MZ36 and 11MN5 deoxyribozyme. For the parent DNA-C3-CSA substrate, 6QG6 and 
6QG8 had kobs = 0.40 h–1 and 50% yield and kobs = 0.40 h–1 and 41% yield after 60 h 
incubation, respectively. However, none of the 6QG deoxyribozymes were active with 
DNA-HEG-CSA.  
 
Figure 2.32 Kinetic screening of individuals 6QG clones. Reaction conditions: 50 mM 
HEPES, pH 7.5, 150 mM NaCl, 2 mM KCl, 40 mM MgCl2, and 20 mM MnCl2 at 37 ºC. Time 
points were taken at 30 s, 3 h, 30 h.  
 
Figure 2.33 Sequence alignment of 6QG sequences. Highlighted sequences were prepared 
by solid-phase synthesis for kinetic characterization. Asterisks denote sequences that 
were studied in greater details. 
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For simplicity, two 6QG deoxyribozymes, 6QG6 and 6QG18, were assayed with the free 
CYA substrate (Fig. 2.34). For the free CYA, 6QG6 and 6QG18 had kobs = 0.22 h–1 and 
41% yield and kobs = 0.30 h–1 and 45% yield after 60 h incubation. Compared to the 
previously obtained deoxyribozymes 11MN5, 6QG6 was 4-fold faster and 6QG18 was 6-
fold faster. However, the 6QG deoxyribozymes showed no better reactivity with all the 
Tyr and Ser variants than the 15MZ36 deoxyribozyme. 
 
Figure 2.34 Kinetic plots of the 6QG6 and 6QG18 deoxyribozyme. They showed 
comparable activities as 15MZ36.  
 
2.2.17 Redirection from the DNA-TEG-OH selection using DNA-C3-CYA (NZ 
selection)  
As part of the comprehensive effort to achieve CYA and CSA reactivity, we 
redirected the MY selection effort (DNA-TEG-OH selection) to use DNA-C3-CYA. The 
redirection selection was called the NZ selection. The round 11 pool from the selection 
with DNA-TEG-OH (MY selection) was continued for two rounds with the DNA-C3-
CYA substrate with 2 h incubation. A time pressure was applied by decreasing the 
incubation time from 2 h to 10 min. Two additional rounds were carried out in 10 min 
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incubation. The activity reached to 30% (10 min incubation) in round 15 and the pool of 
deoxyribozyme was cloned and sequenced (Fig. 2.35).  
 
Figure 2.35 MY and NZ selection progression. The MY selection was initiated with N40 pool 
using the DNA-TEG-OH substrate. Reaction conditions: 50 mM HEPES, pH 7.5, 150 mM 
NaCl, 2 mM KCl, 40 mM MgCl2, and 20 mM MnCl2 at 37 ºC. The selection effort was 
redirected with DNA-C3-CYA using the round 11 of the MY selection. The redirection effort 
from DNA-TEG-OH to DNA-C3-CYA was denoted as the NZ selection. After two rounds of 
redirection, the incubation time was decreased to 10 min. The pool of NZ deoxyribozymes 
was cloned and sequenced at round 15. The blue asterisk denotes the round and activity 
(30%) of where the NZ selection was cloned. 
 
2.2.18 Cloning and sequencing of NZ deoxyribozymes and their kinetics 
Of the 23 clones surveyed, 22 clones were active (>5 % activity; Fig. 2.36). 
Sequences were obtained for 10 of the active clones (Fig. 2.37). We examined the kinetic 
activity of 15NZ11 and 15NZ16 with DNA-C3, HEG-CYA substrates as well as free 
CYA. For the DNA-C3-CSA substrate, 15NZ11 and 15NZ16 had kobs = 0.34 h–1 and 57% 
yield and kobs = 0.10 h–1 and 47% yield after 60 h incubation, respectively. However, none 
of the 15NZ deoxyribozymes were active with DNA-HEG-CSA. For the free CYA, 
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15NZ11 and 15NZ16 had kobs = 0.24 h–1 and 44% yield and kobs = 0.01 h–1 and 50% yield 
after 60 h incubation, respectively (Fig. 2.38). 
 
Figure 2.36 Kinetic screening of individuals 15NZ clones. Reaction conditions: 50 mM 
HEPES, pH 7.5, 150 mM NaCl, 2 mM KCl, 40 mM MgCl2, and 20 mM MnCl2 at 37 ºC. Time 
points were taken at 1 h, 30 h. The sequences were obtained with the clones marked with 
an asterisk. 
 
 
Figure 2.37 Sequence alignment of 15NZ sequences. Highlighted sequences were 
prepared by solid-phase synthesis for kinetic characterization. 
 
 
 
Figure 2.38 Kinetic plots of the 15NZ11 and 15NZ16 deoxyribozyme. 
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2.2.19 Dependence of 15MZ36 free CYA reactivity on the 3′-terminal 
composition of the deoxyribozymes  
15MZ36 was identified from an in vitro effort that was employed entirely using a 
tethered tripeptide substrate. The 3′-terminal of the deoxyribozyme was always Watson-
Crick basepaired to the substrate either with the C3 or HEG-tethered tripeptide. 
Therefore, we evaluated the 15MZ36 activity with the free CYA substrates with changes 
to the composition of the 3′-terminal of the deoxyribozyme. First, we demonstrated that 
truncating the 3′-terminal of the deoxyribozymes lead to substantial decrease of the 
reactivity. Second, we showed that changing the helper oligonucleotide to either DNA 
terminated TEG, or HEG tether, rather than having a free 3′-OH terminus did not affect 
the activity of 15MZ36 toward free CYA substrate (Fig. 2.39). Two conclusions can be 
made from these studies. First, the 15MZ36 deoxyribozyme required the 3′-terminal to be 
double-stranded DNA. Second, the tether atoms did not contribute to the reactivity of 
15MZ36. In related assays, similar observations were made for 9NG14 and 11MN5. 
 
Figure 2.39 Dependence of 15MZ36 activity on the 3′-terminal composition of the 15MZ36. 
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Figure 2.39 (cont.) Dependence of 15MZ36 activity on the 3′-terminal composition of the 
15MZ36. 15MZ36 was used as an illustrative example. (A) Kinetic assays were performed in 
two formats: without the helper oligonucleotide or with truncating the 3′-terminal of 
15MZ36. Both the omission of the helper oligonucleotide and the truncation of the 3′-
terminal of 15MZ36 led to substantial decrease of activity. (B) Various helper 
oligonucleotides terminating with different tethers were used to assay the activity of 
15MZ36 with free CYA. The comparable activity of 15MZ36 with different helper 
oligonucleotides terminating with different tether illustrates that the tether atoms do not 
contribute to the activity of 15MZ36.  
 
2.2.20 Dependence of 15MZ36 activity on divalent metal cofactors  
We examined the divalent metal cofactor requirements for 10KC3, 11MN5 and 
15MZ36-catalyzed reactivity with the DNA-C3-CYA substrate. Metal cofactors 40 mM 
MgCl2, and 20 mM MnCl2 were employed during the selection. 10KC3, 11MN5 and 
15MZ36 depend on Mn2+ ions only. The concentration of MnCl2 requirement was 
assayed. From these assays, the Kd,app with MnCl2 of 10KC3 was estimated to be ~5 mM 
(Fig. 2.40). 11MN5 had a Kd,app with MnCl2 ~2 mM. 15MZ36 had a Kd,app with MnCl2 < 1 
mM (Fig. 2.41). 
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Figure 2.40 Kinetic assay of 10KC3-catalyzed tethered CYA reactivity with various 
concentrations of Mn2+. Metal cofactors 40 mM MgCl2, and 20 mM MnCl2 were employed 
during the selection. 10KC3-catalyzed Tyr reactivity only depends on Mn2+ ions. Reaction 
conditions: 50 mM HEPES, pH 7.5, 150 mM NaCl, 2 mM KCl, 40 mM MgCl2, and various 
concentrations of MnCl2 at 37 ºC. Time points were taken at 5 min, 3 h, 25 h. From these 
assays, the Kd,app with MnCl2 of 10KC3 was estimated to be less than 5 mM. Experiments 
were performed by Sarah Kwon (SCK). 
 
 
Figure 2.41 Kinetic assay of 10KC3, 11MN5, 15MZ36-catalyzed tethered CYA reactivity with 
various concentrations of Mn2+. Metal cofactors 40 mM MgCl2, and 20 mM MnCl2 were 
employed during the selection. 10KC3, 11MN5 and 15MZ36 only depend on Mn2+ ions. 
Reaction conditions: 50 mM HEPES, pH 7.5, 150 mM NaCl, 2 mM KCl, 40 mM MgCl2, and 
various concentrations of MnCl2 at 37 ºC. Time points were taken at 5 min, 3 h, 21 h. From 
these assays, the Kd,app with MnCl2 of 10KC3 was estimated to be ~5 mM. 11MN5 had a 
Kd,app with MnCl2 ~2 mM. 15MZ36 had a Kd,app with MnCl 2 < 1 mM. Experiments were 
performed by SCK. 
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2.2.21 Effect of lanthanides on 10KC3 catalysis 
 
Triavalent lanthanide ions have been used as alternative catalytic cofactors for a 
RNA-cleaving deoxyribozyme.16 To assess the effect of lanthanides on 10KC3-catalyzed 
short-tethered CYA ligation to the RNA substrate, kinetic assays were performed with 
lanthanide ions, Eu3+ or Yb3+, along with addition of 5 mM Mn2+. It was found that both 
lanthanide ions inhibit the reactivity of 10KC3 (Fig. 2.42). 
 
Figure 2.42 The effect of lanthanide ions (Eu3+ or Yb3+) on 10KC3. Reaction conditions: 50 
mM HEPES, pH 7.5, 150 mM NaCl, 2 mM KCl, 40 mM MgCl2, and 5 m MnCl2 at 37 ºC. The 4-
fold decrease of Mn2+ (from 20 mM to 5 mM) allows us to readily discern the effect of the 
lanthanide ions on 10KC3 catalysis. Time points were taken at 5 min, 3 h, 24 h. Lanthanide 
ions inhibit 10KC3 catalysis, leading to a lanthanide concentration-dependent decrease in 
product formation. Experiments were performed by SCK. 
 
2.2.22 Determination of Kd,app for 15MZ36 with free CYA tripeptide  
We examined the dependence of 15MZ36 activity on the concentration of the free 
CYA substrate. The Kd,app value was found to be on the order of 1 mM, with 65% yield at 
60 h with 3 mM CYA (Fig. 2.43). The result of the Kd,app value in the order of mM was 
not unexpected as the various versions of tethered CYA substrates were used in all the 
selection efforts. 
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Figure 2.43 Determination of Kd,app for 15MZ36 with the free CYA tripeptide substrate. (A) 
15MZ36 ligation yield was evaluated with CYA concentrations of 50, 100, 200, and 500 µM 
as well as 1, 2, and 3 mM. Data were fit to the standard equation Y = Ymax•C/(Kd + C), where 
C is the tripeptide concentration. (B) From the kobs data, the Kd,app value for the free CYA 
tripeptide substrate was 1.8 ± 0.5 mM. (C) From the yield data, the Kd,app value was 420 ± 90 
µM. 
 
2.2.23 Multiple turnover assay of 15MZ36  
We studied 15MZ36 activity under multiple turnover conditions. To do this, we 
assayed the DNA-catalyzed reaction with 10% (0.1:1; deoxyribozyme:RNA ) of the 
deoxyribozymes relative to the 3′-32P-radiolabeled 5′-triphosphorylated RNA substrate, 
along with excesses of the helper oligonucleotide and free CYA substrate. When the 
assay was performed with 100% deoxyribozyme (1:1; deoxyribozyme: RNA) with the 
RNA substrate the ligation yield was ≤8%, providing no evidence for turnover (Fig. 
2.44A). It was reasoned that reducing the number of base pairs between the 
deoxyribozyme and the RNA substrate would encourage the product dissociation. 
Therefore, a set of deoxyribozyme was designed with a 5′-binding arm forming between 
7–11 base pairs with 5′-triphosphorylated RNA substrate to modulate potential product 
inhibition (which was frequently observed with many deoxyribozymes). However, again 
no evidence for multiple turnover was observed (Fig. 2.44B).  
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Figure 2.44 Multiple turnover assays with 15MZ36. (A) 15MZ36 forms 17 base pairs with the 
RNA substrate. Kinetic plots of 100% or 10% of the deoxyribozyme was used relative to 
the 3′-32P-radiolabeled 5′-triphosphorylated RNA substrate. No evidence for multiple 
turnover was observed. (B) Kinetic plot of deoxyribozymes with reduced number of base 
pairs with the RNA substrate to foster product dissociation.  
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2.2.24 Characterization of the Tyr-RNA and Ser-RNA Ligation Products 
To characterize the product, MALDI mass spectrometry was obtained for the 
representative ligations products, as depicted in Fig. 2.45 with representative data for the 
15MZ36 DNA-C3-CSA–RNA product. To further support with the product assignment, 
DTT treatment and RNase T1 digestions were separately performed on the ligation 
product. DTT treatment led the reduction of the disulfide bond, and RNase T1 cleaves 
specifically every 3′ end of single-stranded G residues. Both the DTT treatment and 
RNase T1 digestion led to the expected masses. Analogous mass analyses were obtained 
for several other ligation products, including the CYA–RNA product formed by 
15MZ36.Table 2.1 shows the results of the masses of several other ligation products. 
 
Figure 2.45 MALDI mass spectrometry analyses of the 15MZ36 DNA-C3-CSA–RNA ligation 
product and its DTT and RNase T1 digestions.  
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deoxyribozyme and substrate mass 
calcd.  a 
mass 
found 
error, % 
(found –  calcd.) 
10KC3 with DNA-C3-CYA    
ligation product 12026.2 12025.6 –0.01 
DTT digestion (L product) b 5947.7 5950.2 +0.04 
DTT digestion (R product) b 6078.9 6080.2 +0.02 
RNase T1 digestion 6782.9 6781.2 +0.03 
    
11MN5 with DNA-HEG-CYA    
ligation product 12371.0 12369.2 –0.02 
DTT digestion (L product) b 6293.0 6295.2 +0.04 
DTT digestion (R product) b 6079.0 6079.3 +0.01 
RNase T1 digestion 7126.7 7126.8 0.00 
    
15MZ36 with DNA-C3-CSA    
ligation product 11949.6 11948.1 –0.01 
DTT digestion (L product) b 5947.7 5948.9 +0.02 
DTT digestion (R product) b 6002.6 6002.7 0.00 
RNase T1 digestion 6705.3 6714.8 +0.14 
    
15MZ36 with untethered CYA    
ligation product 6167.2 6165.9 –0.02 
DTT digestion c 6078.0 6078.7 +0.01 
RNase T1 digestion 923.8 d 924.5 d +0.08 
 
Table 2.1. MALDI mass spectrometry analyses of key deoxyribozyme products and their DTT and 
RNase T1 digestions. All MALDI mass spectra were obtained in the mass spectrometry 
laboratory of the UIUC School of Chemical Sciences. See the Experimental Procedures for 
reaction details. 
a Calculated masses are for [M–H]– 
b “L product” refers to the left-hand product (DNA anchor oligonucleotide + tethered thiol), and “R 
product” refers to the right-hand product (tripeptide + RNA), as shown in Fig. 2.44. 
c When the substrate is a free tripeptide, the DTT digestion leads only to the tripeptide-RNA 
product. 
d Mass spectrum obtained in positive ion mode, [M+H]+.  
 
 
2.2.25 Sequence alignments and relationships among the new deoxyribozymes 
The sequence similarities between of each of the sequences were compared (Fig. 
2.46). Each of the more active deoxyribozymes 9NG14, 11MN5, and 15MZ36 differ 
from the original 10KC3 by numerous mutations (10 for 9NG14; 9 as well as three 
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inserted nucleotides for 11MN5; and 8 as well as one inserted nucleotide for 15MZ36). 
Upon aligning the representative sequences of the selection efforts, three entirely or 
largely conserved nucleotide blocks could be observed. The many shared nucleotides 
suggest the emergence in this study of one overall motif for DNA-catalyzed reactivity of 
Tyr/Ser side chains in peptide substrates.  
 
Figure 2.46 Sequence alignment of the representative deoxyribozyme from the Ser/Try 
selection efforts. Three nucleotides blocks (in grey) were observed, suggesting a common 
motif for DNA-catalyzed reactivity of Tyr/Ser side chains in peptide substrates.  
 
2.2.26 Nucleotide mutation analysis of 15MZ36 and 10KC3 
15MZ36 differs in 8 as well as one more inserted nucleotide compared to the 10KC3, yet 
the reactivity is drastically different between 15MZ36 and 10KC3. We examined the role 
of the 8 and one inserted nucleotide of 15MZ36. To achieve this, we studied the effect of 
loss-of-function 15MZ36 mutants, i.e., mutating the nucleotides of 15MZ36 to the 
nucleotides of 10KC3 in a specific position) as well as the effect of gain-of-function 
10KC3 mutants, i.e., mutating the nucleotides of 10KC3 to the nucleotides of 15MZ36 in 
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a specific position. From these studies (performed by Yoonhee Anh, an undergraduate 
student), the following was concluded. 
First, the identity of position 29 is important for 15MZ36 as well as 10KC3. The 
kinetics studies of 15MZ36: G29∆, 10KC3: ∆29G, and 15MZ36: G29A with C3 and 
HEG-CYA substrates revealed that the nucleotide in position 29 is essential for the 
deoxyribozyme. Both the identity and presence of the nucleotide at this position play a 
significant role. The importance of G in position 29 was shown through the fact that 
15MZ36 completely lost its activity when guanine was deleted and when guanine was 
replaced with adenine. This suggested that adenine, although it is similar in size to 
guanine, was not adequate to retain the activity of the deoxyribozyme. Also, the 
importance of the guanine was verified with the completely loss of activity with the 
15MZ36: G29∆, in which the guanine was absent. In a similar manner, position 29 of 
10KC3 seems to be critical because it lost its activity when guanine was substituted at 
position 29 (in the original 10KC3 sequence, G is absent). Thus, it was concluded that 
15MZ36 requires guanine at position 29 and 10KC3 requires that the position remained 
unoccupied.  
Second, the identity of position 41 is critical for the function of 15MZ36. We 
examined the kinetics of 15MZ36:C41G and 10KC3:G41C. It was found that 
15MZ36:C41G completely lost its activity when C was replaced with G, indicating that 
the transversion was not tolerated. Whereas, 10KC3:G41C mutant is tolerated with a 
slight decrease in activity compared to the original 10KC3 sequence. 
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2.3 Summary 
In this chapter, deoxyribozymes were found to catalyze Tyr-RNA or Ser-RNA 
nucleopeptide linkage formation when the peptide was either tethered to a DNA anchor 
oligonucleotide or, in the case of Tyr, untethered (free). Several new deoxyribozymes for 
Tyr modification (and several for Ser modification as well) were identified via in vitro 
selection. The best new deoxyribozyme from these efforts, 15MZ36, catalyzes covalent 
Tyr modification of a free Cys-Tyr-Ala substrate with kobs = 0.5 h–1 (t1/2 83 min) with up 
to 65% yield.  
Fig. 2.47 illustrates the key selection efforts that were performed in this 
comprehensive study. The KC selection was initiated with the DNA-C3-CYA using a N40 
pool, which lead to the discovery of the 10KC3 deoxyribozymes. To seek 
deoxyribozymes that function better with the free CYA substrate, different selection 
efforts were performed. A reselection using the DNA-C3-CYA substrate with the 25% 
partially randomized 10KC3 pool led to the discovery of 9NG14 with improved activity 
with the CYA substrate 9NG14: 40% yield in 60 h (kobs = 0.063 h–1, t 1/2 of 11h), ~ 30 
fold faster and with a 4-fold improvement in yield compared to 10KC3. MN selection 
was performed with DNA-HEG-CYA from using a N40 pool; and 11MN5 showed 
significant improvement toward the free CYA with 55% yield in 60 h (kobs = 0.05 h–1, t 1/2 
of 14 h, ~ 30-fold faster and 5-fold improvement in yield compared to 10KC3). To seek 
DNA-catalyzed Ser reactivity, we initiated the MZ selection effort with the DNA-TEG-
OH using a N40 pool. Upon seeing activity with the DNA-TEG-OH, we redirected the 
selection effort using DNA-C3-CSA as a substrate. From the MZ selection effort, we 
identified 15MZ36 which was the best among all the selection efforts described in this 
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chapter. To explore sequences closely related to 15MZ36. We initiated a selection effort 
using the partially (25%) randomized 15MZ36 with DNA-C3-CYA, denoted as the QG 
selection. Compared to the previously obtained deoxyribozymes 11MN5, 6QG6 was 4-
fold faster and 6QG18 was 6-fold faster in catalyzing free CYA reactivity. Furthermore, 
the DNA-TEG-OH selection was redirected to use DNA-C3-CYA, which was the NZ 
selection. 15NZ11 showed comparable activity (~2-fold slower with CYA, similar in 
yield) compared to that of 15MZ36.  
 
Fig. 2.47 Comprehensive study using various tethered substrates during the selection. 
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From all the selection efforts reported in this chapter, several implications could be 
drawn to direct the design of future selection efforts. First, 15MZ36 was identified from 
the selection effort starting with the DNA-TEG-OH substrate and redirected using the 
DNA-C3-CSA as its substrate. For future experiments, redirection maybe a good strategy 
to obtain activity. Second, including a DNA substrate terminating with a hexa(ethylene) 
glycol and covalently linked to a peptide (DNA-HEG-CYA) in the selection led to the 
identification of deoxyribozymes with improved kinetics in the context of DNA-
catalyzed nucleopeptide ligation. In the future, a substrate with a polyethylene glycol 
linker conjugated with a peptide could be employed during selection. Third, selection 
efforts in which the peptide is present free in solution should be employed, which should 
potentially leads to the identification of deoxyribozymes with higher affinity to the 
peptide. 
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2.4 Materials and Methods 
2.4.1 Preparation of oligonucleotide, DNA-Cys-Xaa-Ala conjugates, Cys-Xaa-Ala 
small molecules, and 25% partially randomized pool 
Oligonucleotides. Standard DNA oligonucleotides were prepared at IDT (Coralville, 
IA). The 5′-triphosphorylated RNA substrate sequence, 5′-GGAAGAGAUGGCGACGG-3′, was 
prepared by in vitro transcription with T7 RNA polymerase and a chemically synthesized 
DNA template. The 3′-thiol modifier solid support was purchased from Glen Research. 
Denaturing PAGE with running buffer 1 × TBE (89 mM Tris, 89 mM boric acid and 2 
mM EDTA, pH 8.3) was employed to purify all oligonucleotides including DNA-Cys-
Xaa-Ala. N40 DNA with primer-binding regions: 5′-CGAAGTCGCCATCTCTTC-N40- 
ATAGTGAGTCGTATTAAGCTGATCCTGATGG-3′ was used. Two primers were used in PCR. 
Primer 1 was 5′-(AAC)4XCCATCAGGATCAGCTTAATACGACTCACTAT-3′ [ X = hexa(ethylene 
glycol) to stop Taq polymerase ] and Primer 2 was 5′-CGAAGTCGCCATCTCTTC-3′. Primer 2 
is phosphorylated to allow ligation to the RNA substrate.  
 
Preparation of DNA-Cys-Xaa-Ala conjugates. Four small molecules, PyS-S-Cys-Xaa-
Ala, where Xaa denotes the amino acid, Tyr, Ser, Lys, or Ala were previously 
synthesized in our laboratory by a solution-phase method1. (Scheme 1.1). Fmoc-
protected Xaa 1 were coupled to N-methylalanine using the benzotriazol-1-yl-
oxytris(dimethylamino)phosphonium hexafluorophosphate (BOP) coupling reagent to 
generate the corresponding Fmoc-dipeptide 2. The Fmoc was removed with piperidine 
and the dipeptide 3 was coupled to Fmoc-Cys(tBu)-OH. Fmoc-tripeptide 4 was treated 
with piperidine to yield tripeptide 5. The N-terminus was acylated to yield 6. Subsequent 
TFA treatment deprotected the side chain of the Xaa generated 7. The tert-butyl disulfide 
was reduced, and the reaction with pyridyl disulfide yielded PyS-S-Cys-Xaa-Ala 8. PyS-
S-Cys-Xaa-Ala small molecules were coupled to the anchor DNA via a disulfide bond. 
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Thus, DNA with a 3’-thiol was required for conjugation with the PyS-S-Cys-Xaa-Ala 
small molecules. The Cys t-butyl disulfide was exchanged for a pyridyl disulfide by 
reduction with DTT and activation with 2,2′-dipyridyl disulfide. The final PyS-CXA 
tripeptides were analyzed by 1H NMR and 13C NMR spectroscopy as well as by ESI 
mass spectrometry.  
 
Scheme 2.1 Synthesis of PyS-S-Cys-Tyr-Ala. The 2-chlorotrityl group is abbreviated as ClTr. 
Tripeptides with Xaa = Ser, Lys or Ala were prepared using the same scheme. 
Each PyS-CXA tripeptide was conjugated to DNA to form DNA-C3-CXA or DNA-HEG-
CXA. DNA-C3-SS-C3-OH or DNA-HEG-SS-C3-OH was reduced with DTT (50 mM 
HEPES, pH 7.5, 50 mM DTT, 37 °C, 2 h) and precipitated with ethanol. The conjugation 
reaction was performed using 3 nmol of DNA-C3/HEG-SH in 20 µL of 50 mM 
triethylammonium acetate, pH 7.0, 10 nmol of PyS-CXA in 5 µL of formamide, 15 µL of 
water, and 10 µL of additional formamide (total volume 50 µL) at 37 °C for 4 h, followed 
by 20% PAGE. 
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Characterization of the tripeptide substrates CYA, CSA, and CAA 
CYA tripeptide 
 
1H NMR (400 MHz, DMSO-d6): δ 9.19 (s, 1H), 8.43 (d, J = 4.8 Hz, 1H), 8.30 (d, J = 8.0 Hz, 1H), 8.04 (d, 
J = 7.7 Hz, 2H), 7.81 (td, J = 7.7 Hz, <2 Hz, 1H), 7.74 (d, J = 8.1 Hz, 1H), 7.53 (m, 1H), 7.24 (dd, J = 6.5, 
5.0 Hz, 1H), 6.97 (d, J = 8.4 Hz, 2H), 6.61 (d, J = 8.4 Hz, 2H), 4.49 (td, J = 8.5, 5.1 Hz, 1H), 4.38 (td, J = 
8.1, 5.0, 1H), 4.16 (quintet, J = 7.1 Hz, 1H), 3.10 (dd, J = 13.3, 4.9 Hz, 1H), 2.93-2.87 (m, 2H), 2.68 (dd, J 
= 13.9, 8.8 Hz, 1H), 2.54 (d, J = 4.6 Hz, 3H), 1.83 (s, 3H), 1.15 (d, J = 7.2 Hz, 3H) ppm. 
 
 
13C NMR (126 MHz, DMSO-d6): δ 172.01, 170.08, 169.42, 169.37, 158.85, 155.70, 149.45, 137.63, 
130.04, 127.30, 121.05, 119.20, 114.73, 54.12, 51.87, 48.12, 40.58, 36.30, 25.41, 22.35, 18.06 ppm. 
ESI-HRMS: m/z calcd. for C23H29N5O5S2 [M+H]+ 520.1688, found 520.1705 (∆m +0.0017, error +3.3 
ppm). 
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CSA tripeptide 
 
1H NMR (400 MHz, CD3OD): δ 8.47 (ddd, J = 5.0, 1.6, 1.2 Hz, 1H), 7.82-7.75 (m, 2H), 7.24 (ddd, J = 6.5, 
4.9, 1.9 Hz, 1H), 4.67 (dd, J = 8.5, 5.5 Hz, 1H), 4.39 (t, J = 5.7 Hz, 1H), 4.30 (q, J = 7.3 Hz, 1H), 3.87 (dd, 
J = 10.9, 5.2 Hz, 1H), 3.73 (dd, J = 10.8, 6.0 Hz, 1H), 3.29 (dd, J = 13.8, 5.6 Hz , 1H), 3.06 (dd, J = 13.9, 
8.5 Hz, 1H), 2.69 (s, 3H), 1.99 (s, 3H), 1.32 (d, J = 7.3 Hz, 3H) ppm. 
 
 
13C NMR (101 MHz, CD3OD): δ 175.46, 173.68, 172.75, 172.22, 160.66, 150.82, 139.27, 122.79, 121.84, 
62.95, 57.09, 54.35, 50.79, 41.83, 26.49, 22.62, 17.93 ppm. 
 
ESI-HRMS: m/z calcd. for C17H25N5O5S2 [M+Na]+ 466.1185, found 466.1187 (∆m +0.0002, error +0.4 
ppm). 
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CAA tripeptide 
 
1H NMR (500 MHz, CD3OD): δ 8.43 (ddd, J = 4.9, 1.7, 1.0 Hz, 1H), 7.83-7.77 (m, 2H), 7.24 (ddd, J = 6.0, 
4.9, 2.5 Hz, 1H), 4.64 (dd, J = 8.6, 5.4 Hz, 1H), 4.30 (q, J = 7.2 Hz, 1H), 4.27 (q, J = 7.2 Hz, 1H), 3.30 (dd, 
J = 13.9, 5.4Hz, 1H), 3.07 (dd, J = 13.9, 8.6 Hz, 1H), 2.71 (s, 3H), 1.99 (s, 3H), 1.36 (d, 7.2 Hz, 3H), 1.29 
(d, 7.2 Hz, 3H) ppm. 
 
 
13C NMR (101 MHz, CD3OD): δ 175.40, 174.52, 173.62, 172.59, 160.69, 150.62, 139.24, 122.74, 121.77, 
54.20, 51.10, 50.60, 41.69, 26.51, 22.66, 18.19, 17.69 ppm. 
 
ESI-HRMS: m/z calcd. for C17H25N5O4S2 [M+H]+ 428.1426, found 428.1422 (∆m –0.0004, error –0.9 
ppm). 
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25% Partially randomized N40 pool preparation. Pre-mix solutions were made in which 
75% of the oligonucleotide in that position was the same base as in the original 
nucleotide, and in the remaining 25% of the oligonucleotide, that position had an equal 
chance of being any of the other three bases.  
All the standard stock solutions of phosphoramidite were 0.1 M. In general, an upper 
estimate of 200 µL of the phosphoramidite solution was required for each coupling by an 
ABI 394 DNA synthesizer. Also, a minimum 1000 Å size pore size controlled pore glass 
(CPG) was used to minimize the steric effect of the long nucleotide synthesis. Below is 
the method to prepare 1 mL of four 25% partially randomized phosphoramidite stock 
solution. The calculation took into account the relative coupling efficiencies of the four 
phosphoramidites (A = 0.2, G = 0.26, C = 0.24. T = 0.30). 
N* denotes the 25 % partially randomized solution, and N denotes the 0.1 M 
phosphoramidite stock. 
A* = A (799 µL) + G (68 µL) + C(74 µL) + T (59 µL) = 1000 µL 
G* = A (106 µL) + G (735 µL) + C(88 µL) + T (71 µL) = 1000 µL 
C* = A (101 µL) + G (77 µL) + C(755 µL) + T (67 µL) = 1000 µL 
T* = A (116 µL) + G (89 µL) + C(97 µL) + T (697 µL) = 1000 µL 
2.4.2 In vitro selection procedure 
Selection Initiation. To prepare a ligated pool (RNA ligated to the pool), 200 pmol of 
the pool of deoxyribozymes prepared by solid-phase synthesis was ligated to the RNA 
with T4 RNA ligase. In the first round, 400 pmol of L was incubated with 200 pmol of 
the ligated pool in a total volume of 40 µL in 50 mM HEPES, pH 7.5, 150 mM NaCl, 2 
mM KCl, 40 mM MgCl2, and 20 mM MnCl2 at 37 ºC for 2 h. The sample was quenched 
by 40 µL stop solution (80% formamide, 1X TBE [89 mM each Tris and boric acid, pH 
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8.3, 50 mM EDTA], and 0.025% each xylene cyanol and bromophenol blue). The sample 
was purified by 20% PAGE.  
PCR amplification. The ligated product was excised from PAGE, extracted, and 
precipitated with ethanol. The ligated product was resuspended in 83 µL of water and 
PCR- amplified (94 ºC, 30 s; 47 ºC, 30 s; 72 ºC, 30 s) by Taq polymerase with 0.25 µM 
of primer 1 and 1 µM of primer 2 in a total volume of 100 µL for 10 cycles. Phenol-
chloroform-isoamyl alcohol extraction was performed. 1 µL of the PCR product was used 
as the templates for a 30-cycle PCR in a total volume of 50 µL. The PCR product was 
purified by 8% PAGE. The shorter PCR product was excised, extracted and precipitated 
by ethanol. PCR material was ligated to the RNA substrate with T4 RNA ligase and 
purified by 8% PAGE. 
Selection. The ligated material was incubated with 100 pmol of L in a total volume of 
20 µL in 50 mM HEPES, pH 7.5, 150 mM NaCl, 2 mM KCl, 40 mM MgCl2, 20 mM 
MnCl2, 37 ºC for 2 h and purified by 8% PAGE. PCR amplification, ligation and 
selection procedures were performed iteratively until ligation activity reached a plateau. 
2.4.3 Cloning DNA pools, screening clones for ligation activity and sequencing 
Plasmid inserts preparation by PCR. Once ligation activity reached a plateau, cloning 
procedures were performed to isolate individual deoxyribozymes. First, a 1000-fold 
dilution was performed on the 10-cycle PCR product. Second, a 30-cycle PCR in 100 µL 
total volume was performed with 1 µL of the diluted 10-cycle PCR product by Taq 
polymerase with 1 µM cloning primers that encode the stop condons (in bold). Two 
Cloning primers are listed as follows: 5′-TAATTAATTAATTACCCATCAGGATCAGCT-3′, and 
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5′-TAATTAATTAATTACGAAGTCGCCATCTC-3′ 
The PCR products were isolated on a 2% agarose gel, and extracted by Fermentas 
GeneJET extraction kit. Invitrogen TOPO TA cloning kit was used to insert the Taq 
polymerase-amplified PCR product to the plasmid vector. The detailed protocol can be 
obtained from the manual. In the following, only the key procedures were mentioned. 
The subcloning reaction was initiated with the addition of 1 µL of the extracted PCR 
product, 1 µL TOPO vector plasmid, and 1 µL of salt solution (Invitrogen) in a 6 µL total 
volume. The subcloning reaction was incubated at room temperature for 10 min. To 
initiate transformation, 2 µL of the subcloning reaction were added to the One Shot® 
Chemically Competent E. coli. cells and incubated at room temperature for 10 min. The 
cells were heat shock for 30 seconds at 42 oC, followed by addition of 250 µL SOC and 
shaken horizontally at 200 rpm for 37 oC for 1 h. Before plating, 40 µL of X-gal (40 
mg/mL in dimethylformamide) and 40 µL of 100 mM of IPTG were spread on the pre-
warmed Luria-Bertani (LB) plates containing 100 µg/mL of ampicillin. The cells were 
spread on the LB plates and incubated at 37 oC for 18 h.  
After 18 h, 20–40 white colonies were chosen and cultured in 5 mL culture tubes 
containing 3 mL of LB medium containing 40 µg/mL of ampicillin. The cells were 
incubated while shaken at 220 rpm in 37 oC for 18 h. The cells were pelleted and the 
plasmids were isolated by the Fermentas Miniprep Kit.  
Kinetic screening of individual clones. 30-cycle PCR was performed for individual 
clones using 0.25 µM of primer 1 and 1 µM of primer 2 in a total volume of 200 µL. The 
PCR product was ethanol precipitated and isolated by 8% PAGE. The extracted product 
should have a lower limit of 10 pmol after extraction. 0.5 pmol of 3′-32P-radiolabeled 
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RNA substrate, 5 pmol of the PCR product, and 10 pmol of the DNA-C3/HEG-CXA was 
annealed in 5 mM HEPES, pH 7.5, 15 mM NaCl, and 0.1 mM EDTA by heating at 95 °C 
for 1 min and cooling on ice for 5 min. The ligation reaction was initiated by addition of 
stock solutions to a final volume of 10 µL containing 50 mM HEPES, pH 7.5, 150 mM 
NaCl, 2 mM KCl, 40 mM MgCl2, and 20 mM MnCl2. At an appropriate time point, 2 µL 
portion of the reaction was taken out and quenched by 6 µL of stop solution, followed by 
20% PAGE. 
Sequencing. Sequencing was preformed with the reverse primer, M13Rev-24, 5′-
AACAGCTATGACCATG-3′ (Tm = 45 oC). When the initial sequencing result in ambiguous 
nucleotides, the forward primer was used instead. The sequence of the forward primer 
M13For-21 was 5’-GTAAAACGACGGCCAGT-3’ (Tm = 58 oC). The chromatogram was 
analyzed by Chromas and the sequence alignment was obtained by CLC Sequence 
Viewer 6. 
2.4.4 Deoxyribozyme activity assays 
Radiolabeling of 5′-triphosphorylated RNA Substrate. 5′-32P-radiolabeled cytidine 
3′, 5′-bisphosphate (pCp) was prepared by incubating 60 pmol cytidine 3′-
monophosphate (Cp), 40 pmol of γ-32P-ATP, and 10 U of T4 PNK (Fermentas) in 12 µL 
of 1× T4 PNK buffer (50 mM Tris, pH 7.6, 10 mM MgCl2, 5 mM DTT, 0.1 mM 
spermidine, 0.1 mM EDTA) in 10 µL at 37 °C for 2 h. The PNK was inactivated by 
heating the sample at 95 °C for 5 min and cooling on ice for 10 min. The resulting sample 
was assumed to contain 40 pmol of 5′-32P-pCp. The 3′-32P-radiolabeled RNA substrate 
was prepared by ligating 60 pmol of unradiolabeled R to 20 pmol of 5′-32P-pCp using 10 
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U of T4 RNA ligase (Fermentas) in 20 µL of 50 mM Tris, pH 7.5, 5 mM MgCl2, 10 mM 
DTT, 0.05 mM ATP at 37 °C for 12 h, followed by 20% PAGE.  
Kinetic assays with DNA-Anchored tripeptide substrates. The DNA-tripeptide 
substrate is designated as the L (left-hand) substrate, and the 5′-triphosphorylated RNA 
substrate is designated as the R (right-hand) substrate. In each deoxyribozyme assay, R 
was the limiting reagent relative to the deoxyribozyme (E) and the L substrate. A 14 µL 
sample containing 1 pmol of partially 3′-32P-radiolabeled, 10 pmol of E, and 20 pmol of 
L was annealed in 5 mM HEPES, pH 7.5, 15 mM NaCl, and 0.1 mM EDTA by heating at 
95 °C for 1 min and cooling on ice for 5 min. The ligation reaction was initiated by 
addition of stock solutions to a final volume of 20 µL containing 50 mM HEPES, pH 7.5, 
150 mM NaCl, 2 mM KCl, 40 mM MgCl2, and 20 mM MnCl2. Final concentrations were 
50 nM R, 0.5 µM E, and 1 µM L (1:10:20 R:E:L; single-turnover conditions). At 
appropriate times, 1.4 µL aliquots were quenched with 6 µL of stop solution. Before 
PAGE, 100 pmol of a “decoy oligonucleotide” was added to each sample. The decoy 
oligonucleotide was a 60-mer complementary to the enzyme region (~40 nt) along with 
10 nt of binding arm on either side. This decoy oligonucleotide was added to displace the 
deoxyribozyme from the substrate and ligation product. Without the decoy 
oligonucleotide, the gel bands were noticeably smeared, which inhibited proper 
quantification. 
Kinetic assays with free tripeptide substrates. Similar to the procedures above, with 
the exception that that the 20 pmol of DNA-tripeptide substrate was replaced with 20 
pmol of DNA helper oligonucleotide and 20 nmol of free tripeptide was added after the 
annealing step. 50 mM stock solutions of tripeptide were prepared in formamide. Final 
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concentrations were 50 nM R, 0.5 µM E, 1 µM helper oligonucleotide, and 1 mM 
tripeptide substrate (1:10:20:20,000 R:E:helper:tripeptide; single-turnover conditions), 
with 2% formamide by volume. For determining Kd,app of the CYA tripeptide for the 
15MZ36 deoxyribozyme, the concentration of tripeptide was varied between 0 and 3 
mM, with 2% formamide in the final sample in all cases. For experiments in which 
multiple turnover was examined, the concentrations were 0.5 µM R, 50 nM E, 10 µM 
helper oligonucleotide, and 1 mM tripeptide substrate (10:1:200:20,000 
R:E:helper:tripeptide). 
Multiple turnover assays with various 5′-truncated 15MZ36. The kinetic assays were 
performed in a similar manner as the above procedure. The key differences are as 
follows:  
For 100% E reaction, the reaction involved 1 pmol of radiolabeled R along with 9 
pmol of R (10 pmol of R in total), and 10 pmol of E (100%) and 200 pmol of the helper 
oligonucleotide in 1 mM CYA (1:1:20:2000 R:E:helper:tripeptide). 10 pmol of R instead 
of 1 pmol of R was used to avoid making the deoxyribozyme too diluted for the assay 
using 10% E.  
For 10% E reaction, the reaction involved 1 pmol of radiolabeled R along with 9 
pmol of R (10 pmol in total), and 1 pmol of E (10%) and 200 pmol of the helper 
oligonucleotide in 1 mM CYA (10:1:200:20,000 R:E:helper:tripeptide). 
RNase T1 digestion of Ser-RNA and Tyr-RNA products. RNase T1 digestion of DNA-
C3/HEG-CXA–RNA, 100 pmol of ligation product was incubated in 50 mM Tris, pH 7.5, 
2 mM EDTA, and 20 U of RNase T1 (Ambion) in 20 µL total volume at 37 °C for 4 h, 
extracted by phenol/chloroform, precipitated by ethanol, and desalted with C18 ZipTip.  
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For RNase T1 digestion of untethered CYA–RNA, the same procedure was used, except 
extraction and precipitation were omitted. All MALDI mass spectra were obtained in the 
mass spectrometry laboratory of the UIUC School of Chemical Sciences. 
DTT treatment of Ser-RNA and Tyr-RNA products. For DTT reduction, 100 pmol of 
the ligation product was incubated in 50 mM HEPES, pH 7.5, and 50 mM DTT in 20 µL 
total volume at 37 °C for 2 h, precipitated with ethanol, and desalted with C18 ZipTip 
(Millipore).  
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Chapter 3: DNA-Catalyzed Reductive Aminationa  
3.1 Introduction 
This chapter describes a new in vitro selection method that sought DNA catalysts 
which modify the side chain of a free peptide substrate. First, the free peptide was 
allowed to react with the 5′-triphosphorylated RNA. Second, active deoxyribozymes 
were captured by reaction of the peptide N-terminus amino group with an oligonucleotide 
terminating with aldehyde functional groups. Despite the in vitro selection design, we 
identified deoxyribozymes that catalyzes reductive amination reaction using a weakly 
nucleophilic N2-amine of a guanine of the RNA substrate, instead of the originally 
intended N-terminus amino nucleophile. Reductive amination involves in key 
biochemical processes, for example, for amino acid biosynthesis and catabolism using 
amino acid dehydrogenases (oxidases)1 and transaminases (aminotransferases)2-3. In 
vitro, enzymatic reductive amination is important in both laboratory-scale4-7 and 
industrial-scale organic synthesis8-9. Reductive amination may also have been important 
in RNA World scenarios.10-11 The unexpected discovery of DNA-catalyzed reductive 
amination expands the catalytic repertoire of deoxyribozymes. DNA-catalyzed reductive 
amination may have a practical application as a tool for labeling nucleic acids site-
specifically.  
 
a The material described in this chapter has been published. 
Wong, O. Y.; Mulcrone, A. E.; Silverman, S. K., DNA-Catalyzed Reductive Amination. 
Angew. Chem. Int. Ed. 2011, 50, 11679–11684. 
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3.2 Results and Discussion 
3.2.1 Selection design using free tripeptide  
 
In the key selection step of in vitro selection, the active deoxyribozymes are 
physically separated from the inactive DNA sequences. The separation can be done by 
affinity capture, size separation or both. In the Silverman laboratory, we employ the size 
separation method by PAGE. The size separation method was chosen to avoid artifacts 
which could be associated with bead-based selection methods. For bead-based selection 
methods, noncatalytic nucleic acid sequences could be bound to the beads even after 
several stringent washes. As described by previous efforts in Chapter 2, tethered 
tripeptide substrates were used during selection to provide gel-shift selection products, 
which could be readily separated by PAGE (Fig. 3.1A). In this project, a direct selection 
method was designed to find deoxyribozymes that catalyze the ligation of the potential 
nucleophile of a tripeptide to the electrophile of a 5′-triphosphorylated RNA. During the 
selection step, the catalytic active DNA sequences catalyze the ligation of a particular 
peptide to the RNA substrate. However, the additional of the tripeptide to the RNA 
substrate would not have lead to a substantial PAGE shift. Therefore, an alternate 
strategy was developed to enable the isolation of the ligation products after selection. We 
designed a two-stage selection strategy which involved a selection step followed by a 
capture step. In the selection step, deoxyribozymes appended themselves to the free CYA 
tripeptide substrate via reactions between the Tyr nucleophile with the 5′-triphosphate of 
the RNA. In the capture step, an oligonucleotide with 3′ dialdehyde reacts with the N-
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terminus of the free peptide of the selection product via reductive amination, which leads 
to a gel-shift product that could be isolated by PAGE (Fig. 3.1B). 
 
 
 
Figure 3.1 Selection strategy for direct selection using free CYA tripeptide. (A) Previous 
selection efforts used DNA-C3/HEG-CXA as substrates. Although several deoxyribozymes 
were found to function well with CYA, they require CYA in mM concentration. A selection 
that uses CYA directly instead of its tethered version may yield deoxyribozymes that 
function better with the CYA tripeptide than the previous selection efforts described in 
Chapter 2. (B) The new selection design that employed an additional capture step to 
physically isolate the DNA-catalyzed peptide-RNA ligation product. The capture step 
involves a reductive amination of the N-terminus peptide-RNA ligation product with an 
oligonucletiode terminating with two aldehyde functional groups. The oligonucleotide 
containing aldehyde functional groups is denoted as the capture oligonucleotide. 
 
To establish a reliable reductive amination method for the capture step, the reductive 
amination was optimized by using the peptide-RNA-DNA substrate (see Material and 
Methods for preparation of the CYA-RNA-DNA ligation product). The reductive 
amination method was optimized to yield ~50% of the product. 
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3.2.2 Direct selection using free tripeptide (QA selection) 
 
We initiated selection with a free CYA tripeptide to identify deoxyribozymes that 
catalyze the nucleophilic attack of the Tyr-OH to the RNA substrate, denoted as the QA 
selection. We first observed discernable activity (2%) in round 4 and the activity reached 
a plateau in round 8 (35.6%), where the individual clones were sequenced and cloned 
(Fig. 3.2). 
 
Figure 3.2 Direct selection using CYA, denoted as the QA selection. The inset illustrates 
the key round of the QA selection and the independent positive control. The asterisk 
marks the round where deoxyribozymes were cloned and sequenced. 
 
3.2.3 Tripeptide-independent reductive amination catalyzed by QA deoxyribozymes 
 
To test the reductive amination product was a direct result of the DNA-catalyzed free 
peptide ligation to the RNA substrate, we first assayed the uncloned pool with or without 
the free CYA tripeptide substrates, and also with a peptide substrate where its N-terminus 
was blocked with an acetyl group (Fig. 3.3A). The omission of CYA and the absence of a 
primary amine of the free peptide still led to substantial reductive amination product. We 
concluded that the activity did not involve the tripeptide substrate. To make sure the 
observed activity was due to reductive amination, we tested the uncloned pool with or 
without key reactants of the reductive amination. Fig. 3.3 illustrates that CYA was not 
involved in the DNA-catalyzed reductive amination.  
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Figure 3.3 CYA was not involved in the reductive amination reaction. (A) The 7QA 
uncloned pool was assayed in the following conditions: with N-acetylated CYA, with or 
without CYA, and with or without the aldehyde-containing oligonucleotide. The absence of 
aldehyde (omitting the oxidation treatment using sodium periodate to the oligonucleotide 
terminating with a ribonucleotide at the 3′ end) abolished the product formation, 
demonstrating the aldehydes were mandatory in the reaction. Reaction with the N-
acetylated CYA led to substantial activity, showing that the CYA was not involved in the 
reaction as the N-terminus of the CYA was blocked with an acetyl group and thus 
unavailable for the reaction. In addition, in absence of CYA, a significant amount of 
reductive amination product was observed; further supporting CYA was not involved in 
the reaction. (B) The 7QA uncloned pool-catalyzed reaction was further confirmed to be 
reductive amination as omitting key reactants led to no product formation. Without the 
nickel cations or sodium cyanoborohydride, the activity of the uncloned pool was greatly 
suppressed. 
 
3.2.4 Cloning and sequencing of 8QA deoxyribozymes and their kinetics 
The reductive amination product did not involve the tripeptide substrate yet 
interesting as we postulated that the reaction was between the nucleophilic amine of 
nucleobase and the capture oligonucleotide. The 8QA selection was cloned and kinetic 
screening of the clones was performed (Fig. 3.4). We sequenced all the active clones. 
Fig. 3.5 illustrates the unique sequences from the 8QA selection effort. It was found that 
8QA108 was identical to 8QA114; 8QA113 had 1 nt more than 8QA115. 
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Figure 3.4 Kinetic screening of 8QA clones. Time points: 30 s, 2 h, 24 h. All the active 
clones were sequenced.  
 
Figure 3.5 Sequences of new deoxyribozymes that catalyze reductive amination. The first 
seven deoxyribozymes were studied in greater details. The highlighted deoxyribozyme, 
8QA124, had the best rate and yield compared to the others. The last three entries were 
not studied in details. The originally randomized (N40) catalytic region is shown. In each 
deoxyribozyme, the sequence is 5′-CCGTCGCCATCTCTTC-(N40)-ATAGTGAGTCGTATTA-3′. 
 
One of the new deoxyribozymes, 8QA124, catalyzed the reductive amination between 
the RNA substrate and the NaIO4-oxidized capture oligonucleotide in 60–90% yield with 
kobs of 0.37 h–1 (t1/2 1.7 h; Fig. 3.6). The other deoxyribozymes had yields ranging from 
18–55% after 22 h (Fig. 3.7). To confirm the reaction was a deoxyribozyme-catalyzed 
reaction, control experiments were performed with a noncatalytic template strand 
omitting the N40 region, or replacing the N40 region with unpaired T nucleotides (T0, T1, 
T2), the yield in 22 h was only 0.6%, 0.4% and 0.2%. From the T0 results, a conservative 
lower limit of the rate enhancement for 8QA124 was calculated to be 1400 (8QA124 kobs 
of 0.37 h–1 / T0  kobs of 0.00027 h–1). 
 92 
Figure 3.6 Kinetic plot of the activity of 8QA124 deoxyribozyme. The RNA substrate was 3′-
32P-radiolabeled. Incubation conditions: 100 mM NaOAc, pH 5.2, 50 mM NiCl2, and 10 mM 
NaCNBH3 at 37 °C. 
 
Figure 3.7 Catalytic activities of the seven new deoxyribozymes studied in this chapter. 
The assay procedure is described in the Materials and Methods section. kobs values (h–1): 
8QA124 0.37; 8QA102 0.14; 8QA103 0.16; 8QA107 0.092; 8QA111 0.062; 8QA115 0.088; 
8QA122 0.21.  
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Figure 3.8 Dependence of the catalytic activities on the RNA 5′-terminus. Each of the seven 
new deoxyribozymes was assayed with RNA substrates that have either 5′-triphosphate, 
5′-monophosphate, or 5′-hydroxyl terminus. The results of these assays showed that all 
seven deoxyribozymes function well with 5′-monophosphorylated RNA. In contrast, 
reactivity varied widely involving the 5′-hydroxyl RNA substrate. 8QA111 has relatively 
robust activity with 5′-hydroxyl RNA; three of the deoxyribozymes (8QA124, 8QA103, and 
8Q115) have low but detectable activity with 5′-hydroxyl RNA; and the remaining three 
deoxyribozymes (8QA102, 8QA107, and 8QA122) have no detectable activity with 5′-
hydroxyl RNA. 
 
3.2.5 Dependence of the catalytic activities on the RNA 5′-terminus  
We examined the 5′ terminus requirement for all the seven 8QA deoxyribozymes. All 
of the deoxyribozymes functioned well with the 5′-triphosphate RNA as well as 5′-
monophosphate RNA, demonstrating that the originally intended electrophilic 
triphosphate was not involving in the reaction. Six of the seven deoxyribozymes do not 
catalyze the reaction with the 5′-hydroxyl RNA substrate (Fig. 3.8).  
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Figure 3.9 Proposed reductive amination catalyzed by 8QA124 as well as the other 8QA 
deoxyribozymes. 
 
3.2.6 Dependence of the catalytic activities on NaIO4, Ni2+ and NaCNBH3 
 
To further confirm that the reaction catalyzed by the 8QA deoxyribozymes was 
reductive amination, we assayed each of the deoxyribozymes to find if they required 
NaIO4, Ni2+ and NaCNBH3. NaIO4 was used for oxidation of the precursor capture 
oligonucleotide to the aldehyde-containing capture oligonucleotide. All of the 8QA 
deoxyribozymes strictly required the aldehyde functional groups and Ni2+ for reductive 
amination. We proposed that one of the amino group of a nucleobase on the RNA 
substrate was catalyzed by 8QA deoxyribozymes to react with the aldehyde-containing 
capture oligonucleotide to from an adduct product (Fig. 3.9). Mass spectrometry analyses 
and biochemical studies were performed to provide evidence for the proposed reaction.  
We assayed each of the deoxyribozymes for their requirement for NaIO4 (used for 
oxidation of the precursor capture oligonucleotide to the aldehyde-containing capture 
oligonucleotide), Ni2+, and NaCNBH3. The 8QA deoxyribozymes strictly require NaIO4, 
Ni2+, and NaCNBH3. The stringent requirement of key reductive amination component 
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supported that the 8QA deoxyribozymes catalyzed reductive amination. Fig. 3.10 
provides an illustrative example of how 8QA deoxyribozymes catalysis require NaIO4, 
Ni2+, and NaCNBH3. 
 
Figure 3.10 Dependence of the catalytic activities on NaIO4, Ni2+, and NaCNBH3, illustrated 
with data for 8QA124. Data for each of the other six studied deoxyribozymes were similar. 
Incubation conditions: 100 mM NaOAc, pH 5.2, 50 mM NiCl2, and 10 mM NaCNBH3 at 37 °C 
(omitting Ni2+ or NaCNBH3 as indicated). The “– NaIO4 experiment” was performed by 
omitting NaIO4 during preparation of the capture oligonucleotide. Time points were taken 
at 30 s, 4 h, and 22 h. The yield for the “– NaCNBH3” experiment at the 22 h time point was 
1.3%. 
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3.2.7 Characterization of the reductive amination product by RNase T1 treatment 
 
To assign and support our proposed product structure, we obtained the mass of the 
product of the reductive amination product by MALDI-TOF mass spectrometry. The 
mass was consistent with a single reductive amination event, in which an exocyclic 
primary amine attacks one of the two available aldehyde functional groups. The 
subseqent reaction which involved the secondary amine attack of the second aldehyde to 
form a morpholine ring was not supported by the mass of the product. To identify the 
nucleophilic amine in the RNA substrate, we digested the reductive amination product 
with RNase T1, followed by MALDI-TOF mass spectrometry analysis. RNase T1 
specifically cleaves every 3′ of single-stranded G residues of the RNA. After RNase T1 
treatment, the truncated product contained two G nucleotides, indicating that the first G 
nucleotide counting from the 5′-end was not cleaved by RNase T1. With the mass data, 
we proposed that the exocylic amine of the first G nucleotide (G1) attacks one of the 
aldehydes of the capture oligonucleotide. RNAse T1 was not able to cleave G1, which 
was likely due to the covalent linkage between the amine of the G nucleotide base and the 
capture oligonucleotide (Fig. 3.11). Table 3.1 shows the mass of the reductive amination 
product of the rest of the 8QA deoxyribozymes and also their masses after RNase T1 
treatment.  
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Figure 3.11 Proposed structure of the reductive amination product catalyzed by 8QA124 as 
well as the other 8QA deoxyribozymes. (a) RNase T1 cleaved after G2 of the product. (b) 
MALDI-TOF mass analysis of the product, which supported the chemical structure 
assignment.  
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deoxyribozyme RNase 
T1 
mass 
calcd. 
mass 
found 
error, % 
(found –  calcd.) 
8QA124 – T1 11795.5 11795.9 +0.003 
 + T1 a 6878.5 6878.3 –0.003 
 + T1 b 6896.5 6896.6 +0.001 
8QA102 – T1 11795.5 11793.5 –0.02 
 + T1 b 6896.5 6894.5 –0.03 
8QA103 – T1 11795.5 11794.6 –0.008 
 + T1 b 6896.5 6896.4 –0.001 
8QA107 – T1 11795.5 11793.7 –0.02 
 + T1 b 6896.5 6894.4 –0.03 
8QA111 – T1 11795.5 11793.2 –0.02 
 + T1 b 6896.5 6895.3 –0.02 
8QA115 – T1 11795.5 11793.6 –0.02 
 + T1 b 6896.5 6892.0 –0.07 
8QA122 – T1 11795.5 11794.4 –0.009 
 + T1 b 6896.5 6895.8 –0.01 
     
Table 3.1. MALDI mass spectrometry analyses of the reaction products before and after RNase 
T1 digestion. RNase T1 initially creates a 2′,3′-cyclic phosphate terminus that can be hydrolyzed 
to 3′-monophosphate, the ratio of these two products depends on the incubation details.12-14 Both 
products were typically observed in our assays. In the table, data is shown for both products (for 
8QA124) and for the 3′-monophosphate, which was the more abundant of the two products (for 
the other deoxyribozymes). 
a 2′,3′-cyclic phosphate product. 
b 3′-monophosphate product. 
 
3.2.8 Characterization of the reductive amination product by MS/MS experiment 
For additionally support of our assigned structure, we acquired MS/MS data of a 
suitably digested reductive amination product by MALDI-TOF mass spectrometry. First, 
the reductive amination product was treated with RQ1 RNase-free DNase, which digested 
only DNA but not RNA, followed by phenol-chloroform extraction and PAGE 
purification. Three bands were observed. One of three prominent bands was excised, 
extracted, and mass spectrometry was acquired. The mass of the excised band was 
consistent with the sequence 5′-ATa-ggaagagauggcgacgg-3′. The RQ1 DNase-treated 
product was further digested with RNase T1. The product was desalted and mass analysis 
revealed that the product was 5′-ATa-gg-3′. MS/MS experiment was performed with the 
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pentamer product. The diagnostics fragment of the G nucleobase with the G1 ribose as 
well as others fragments that support the assignment were observed (Fig. 3.12). 
 
 
Figure 3.12 MS/MS experiment on a suitably digested fragment of the reductive amination 
product of the 8QA124 deoxyribozyme. The diagnostic fragment, highlighted with an 
asterisk, corresponds to the cleavage between the G1 ribose and the G1 nucleobase. 
Other fragments were also observed that support the structural assignment. 
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3.2.9 The reduction of the second aldehyde group during selection 
Our assigned chemical structure of the reductive amination product depicts that the 
second aldehyde group of the capture oligonucleotide was reduced to an alcohol. The 
alcohol assignment is based on three independent experiments, as follows. First, the 
DNA-catalyzed reductive amination product was not observed to further oxidized to the 
corresponding carboxylic acid by sodium chlorite, NaClO2. The reaction between an 
aldehyde and NaClO2 is known as Pinnick or Lindgren oxidation. In the corresponding 
positive control experiment, the capture oligonucleotide was treated with NaClO2, and 
oxidation was observed by MALDI mass spectrometry analysis. Second, the DNA-
catalyzed reductive amination product was not observed to further react via reductive 
amination with several versions of oligonucleotides terminating with an amine. Whereas, 
the corresponding positive control which involved the capture oligonucleotide readily 
reacted with several versions of oligonucleotides terminating with an amine to yield the 
reductive amination adduct. In addition, the DNA-catalyzed reductive amination product 
was treated with AAASAA hexapeptide with a free N-terminus, and no reductive 
amination adduct was observed. On the contrary, the dialdehyde-containing 
oligonucleotide reacted with the hexapeptide via reductive amination reaction. Third, the 
DNA-catalyzed reductive amination product was treated with biotin-hydrazide, but no 
adduct was observed. In the corresponding positive control, the capture oligonucleotide 
reacted with the biotin-hydrazide readily and adducts were observed. Together, all these 
data establish that the DNA-catalyzed product does not have an aldehyde group. It was 
determined in our assignment that the second aldehyde is an alcohol. 
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Figure 3.13 Direct observation of the reduction of the aldehyde functional groups by 
NaCNBH3 in the capture step incubation condition. The isotopic distributions partially 
obscure the peaks but nonetheless a clear pattern can be observed. The pink dot denotes 
the mass of the oligonucleotide with dialdehyde functional groups and the blue dot 
indicates the mass of the oligonucleotide with the singly reduced alcohol  
 
A reducing equivalent must be present to reduce the second aldehyde of the capture 
oligonucleotide to an alcohol. It was reasoned that the NaCNBH3 could be the reducing 
agent. Under neutral conditions, NaCNBH3 would not readily reduce an aldehyde. 
However, in acidic conditions, NaCNBH3 can be used as reducing agent for aldehydes or 
ketones. In fact, NaCNBH3 is synthetically employed as a reducing agent for aldehydes 
and ketones at pH ~3–4.15-16 For example, it was reported that cyclohexanone was 
reduced to cyclohexanol by NaCNBH3 with 88% yield at pH 4 for 1 h.17 Moreover, there 
were examples7 of aldehyde reduction at pH as high as 5.5. Therefore, we hypothesized 
that the unreacted aldehyde was reduced by NaCNBH3 during the capture step at pH 5.2. 
To show that this scenario is plausible, we validated the hypothesis by incubating a 
hexamer oligonucleotide terminating with aldehyde functional groups. To prepare the 
aldehyde-terminating hexamer oligonucleotide, a hexamer oligonucleotide ending with a 
3′ ribonucleotide A was first treated with NaIO4. The hexamer oligonucleotide 
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terminating with aldehyde functional groups were used instead of the 20 nt long capture 
oligonucleotide because the small hexamer enabled a reliable assignment by MALDI-
TOF mass analysis. Indeed, we observed the reduction of the aldehyde of the hexamer in 
the incubation condition (Fig. 3.13).  
 
3.2.10 8QA deoxyribozymes use alternative borane reducing agents 
We examined the effect of using alternative reducing agents on the DNA-catalyzed 
reductive amination reaction. We replaced the initially used reducing agent NaCNBH3 
with dimethylamine-borane or 2-picoline-borane. In each case of the 8QA 
deoxyribozymes-catalyzed reductive amination, the replacement of other borane reducing 
agents was tolerated (Fig. 3.14). The results show that 8QA deoxyribozymes catalyzed 
poorly or are not involve in the imine reduction. Therefore, the 8QA deoxyribozymes are 
likely to catalyze the first amine nucleophilic attack of carbonyl. 
 
 
Figure 3.14 Sodium cyanoborohydride reducing agent can be substitued by other borane 
reducing agent. Two borane reducing agents were assayed with all 8QA deoxyribozymes. 
In all cases, the 8QA deoxyribozymes tolerate the reducing agent replacement relatively 
well. Shown here are the representative assays performed with 8QA124 to illustrate that 
the replacement of reducing agent is tolerated. The key point of this experiment was not to 
compare the absolute yield of the reductive amination product but to note the substantial 
product formation when alternative reducing agents were used.  
 
 103 
3.2.11 Dependence of the catalytic activities on divalent metal cofactors 
We examined the effect of using various divalent metal ions on the DNA-catalyzed 
reductive amination reaction. We substituted the Ni2+ with other divalent metal ions 
Mg2+, Ca2+ or Mn2+. In each cases of 8QA deoxyribozyme-catalyzed reductive amination, 
the reaction was suppressed when Ni2+ was replaced with other divalent metal ions (Fig. 
3.15). The results were not unexpected as the 8QA deoxyribozymes were identified under 
a selection condition that requires Ni2+. Therefore, the 8QA deoxyribozymes requires Ni2 
to be catalytic active. Also, Ni2+ may serve as a Lewis acid to activate the carbonyl group 
of the aldehyde for the subsequent catalyzed attack of the amine of the G1. However, the 
mechanism on how Ni2+ assists the DNA-catalyzed reductive amination requires 
extensive studies that involve obtaining the high resolution structural information of the 
deoxyribozyme, which is beyond the scope of this thesis work.  
 
Figure 3.15 Ni2+ cannot be replaced by other divalent metal cations. The illustrative PAGE 
of 8QA124 assayed with different divalent metal ions are shown here. Other 8QA 
deoxyribozymes also show the same results. These experiments establish that Ni2+ is 
mandatory for the proper folding of the deoxyribozymes and also may serve as a Lewis 
acid to activate the carbonyl functional group of the aldehyde. 
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3.3 Summary 
In this chapter, we described the selection effort to identify free CYA reactivity. We 
unexpectedly found deoxyribozymes that catalyze reductive amination reaction using a 
weak nucleophilic N2-amine of a guanine of the RNA substrate as the nucleophile, 
instead of the originally intended N-terminus amino nucleophile. One of the 
deoxyribozymes, 8QA124, catalyzes the reductive amination involving the N2-amine of a 
guanine with the RNA substrate with yield ranging from 60–90% and kobs = 0.37 h–1 (t1/2 
1.7 h). This unprecedented discovery expands the scope of reactions catalyzed by DNA 
and is currently being developed as a tool for site-specific labeling nucleic acids. 
 
3.4 Materials and Methods 
3.4.1 Solid phase peptide synthesis 
CYA tripeptide was prepared by standard methods using Fmoc Rink mide MBHA 
resin. The solid phase peptide synthesis (SSPS) procedures can be found in ref. 18. The 
key procedures are described below. 
Materials. Anhydrous DCM and DMF solvents (Fisher) were used. The Fmoc-
protected amino acids, HATU coupling reagent, and the Rink amide MBHA resin were 
purchased from either Novabiochem or Chem-Impex International. A coarse Pyrex fritted 
funnel (40–60 µm pore size) was used for efficient agitation with nitrogen. Deprotection 
solvent contained 20% piperidine and 80% DMF, and it was prepared freshly prior its 
use. SSPS couples Fmoc amino acid from the C-terminus to the N-terminus. To prepare 
CYA tripeptide, the alanine was first coupled, followed by the tyrosine and cysteine. 
Fmoc-Ala-OH (CAS no. 35661-39-3), Fmoc-Tyr(tbu)-OH(CAS no. 71989-38-3), and 
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Fmoc-Cys(tbuthio)-OH (CAS no. 73724-43-3) were used to prepare the CYA tripeptide. 
Beacause SSPS required iterative rinse cycle and deprotection cycle. Therefore, the 
procedure of the rinse cycle and deprotection cycle were described first as follows. 
The rinse cycle consisted of following steps: 
1. 10 mL of DMF was added to the resins and agitated with nitrogen gas. 
2. The solvent was removed by filtration. 
3. The resins were resuspended in 10 mL DMF from a squirt bottle. DMF was 
removed by filtration. 
4. Step 1–3 were repeated for a total four times. 
The deprotection procedure consisted of the following steps: 
1. 10 mL of deprotection solvent was added to the resins and agitated with nitrogen 
gas for 2 min. 
2. The solvent was removed by filtration. 
3. A rinse cycle was performed. 
4. Step 1–3 were repeated for a total three times. 
The Kaiser test was performed, as follows. 
Three solutions were prepared. (Solution A: 5 g ninhydrin in 100 mL of ethanol, 
Solution B: 80 g of phenol in 20 mL of ethanol, Solution C: 2 mL of 1 mM KCN in 98 
mL pyridine) 
1.  ~10 beads were taken from the fritted funnel and placed in a 10 × 75 mm test 
tube. The resins were washed by repeatedly addition and removal of ~1 mL 
methanol with a glass pipette. 
2. Three drops of each solution (A, B and C) were added to the test tube. 
3. The test tube was heated using a heat gun. The tube was shaken gently to avoid 
overheating. 
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4. After 0.5 min of heating, a positive test resulted in resins with purple color, which 
indicates the presence of primary amine functional groups on the resins. A 
negative result would result in a pale yellow to orange color, which indicates there 
were no primary amine function groups on the resins.  
Swell resins. 0.54 mg (0.2 mmol, 0.37 mmol/g) of resin was measured, followed by 
swelling of the resin in a 10 mL of DMF/DCM (v/v; 1:1) for 1 h (3 × bed volume). The 
resins were filtered and washed thoroughly with DMF. 
Resins deprotection. The Fmoc-protecting group of the Rink amide resin was 
removed by the deprotection step, followed by a rinse cycle. The Kaiser test was 
performed and a positive result was observed, indicating the successful removal of the 
Fmoc-protecting group by the base treatment.  
Coupling of Fmoc amino acid. Fmoc protected amino acid (1 mmol, 5 eq.) was first 
activated with HATU peptide coupling reagent (0.98 mmol, 4.9 eq.) and 
diisopropylethylamine (DIPEA, 2 mmol, 10 eq.) for 10 min. The mixture was added to 
the resin, agitated with nitrogen for 1 h. After 1 h, a rinse cycle followed by a Kaiser test 
was performed. A successful coupling would yield a negative result with the Kaiser test. 
Fmoc deprotection. The N-terminus Fmoc protected group was removed by the 
deprotection step, followed by a rinse cycle. A Kaiser test was performed and purple 
resins were observed. The second amino acid coupling was performed after the 
deprotection step. The process was iterated until all of the amino acids were coupled. 
Peptide removal from the solid support by TFA. Resin was transferred to a 20 mL 
disposable scintillation vial containing a small stir bar. Scavenger cocktail (125 µL of 
water, 125 µL of ethanedithiol, and 50 µL of triisopropylsilane) was added to scavenger 
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the t-butyl cations. 5 mL of trifluoroacetic acid (TFA) was added to the vial. The vial was 
capped and the mixture was stirred at room temperature for 3 h. The cleavage mixture 
was filtered through a clean coarse fritted filter. The clear pale yellow cleavage solution 
was transferred to a round-bottom flask and the excess TFA was evaporated by a rotary 
evaporator. 20 mL of cold diethyl ether was added . White precipitates were observed. 
The ether layer was carefully removed by a glass pipette. The ether wash procedures 
were repeated. The residual ether in the round-bottom flask was removed by a rotary 
evaporator, followed by drying under high vacuum for several hours. The peptide was 
purified by HPLC. For the CYA tripeptide, ESI [M+H]+ calcd: 443.6, found: 443.4.  
3.4.2 Preparation of the CYA-RNA-DNA for capture step optimization  
Preparation of CYA-RNA. To test the efficacy of the capture step, a sample 
containing free N-terminus CYA ligated to the RNA and the pool was generated. To 
prepare a CYA-RNA product on the preparative scale, four reactions were performed 
using the following procedure. For each reaction, 1 nmol of 5′-triphosphate RNA, 1 nmol 
of the DNA helper oligonucleotide, and 700 pmol of 15MZ36 were annealed in 5 mM 
HEPES, pH 7.5, 15 mM NaCl, and 0.1 mM EDTA by heating at 95 °C for 1 min and 
cooling on ice for 5 min. 2 µL of CYA (from 50 mM stock solution in DMF) were added, 
and the ligation reaction was initiated by addition of stock solutions to a final volume of 
100 µL containing 50 mM HEPES, pH 7.5, 150 mM NaCl, 2 mM KCl, 40 mM MgCl2, 
and 20 mM MnCl2. The reaction was incubated at 37 °C for 48 h, precipitated with 
ethanol, and purified by 20% PAGE. 
Ligation of CYA-RNA to 5′ 32P- radiolabeled DNA pool. 10 pmol of CYA-RNA was 
ligated to 1 pmol 5′-32P-radiolabeled DNA pool using 1 U of T4 RNA ligase (Fermentas) 
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in 20 µL of 50 mM Tris, pH 7.5, 5 mM MgCl2, and 0.05 mM ATP at 37 °C for 12 h, 
followed by 8% PAGE. In this ligation reaction, DTT was omitted to avoid the reduction 
of the S-tbutyl group of the cysteine. 
3.4.3 In vitro selection procedure 
In the key selection step during each round of selection, the PCR-amplified 
deoxyribozyme pool (estimated 10 pmol) and 50 pmol of helper oligonucleotide 
(complementary to the 3′-binding arm of the deoxyribozyme) were annealed in 14 µL of 
5 mM HEPES, pH 7.5, 15 mM NaCl, and 0.1 mM EDTA by heating at 95 °C for 1 min 
and cooling on ice for 5 min. The sample was brought to final volume of 20 µL 
containing 50 mM HEPES, pH 7.5, 150 mM NaCl, 2 mM KCl, 40 mM MgCl2, 20 mM 
MnCl2, and 1 mM CYA tripeptide (added from 50 mM stock solution in DMF) and 
incubated at 37 °C for 14 h, followed by ethanol precipitation. For the subsequent capture 
step, 200 pmol of capture oligonucleotide was added, and the sample was annealed in 10 
µL of 5 mM HEPES, pH 7.5, 15 mM NaCl, and 0.1 mM EDTA by heating at 95 °C for 1 
min and cooling on ice for 5 min. The sample was then brought to final volume of 20 µL 
containing 100 mM NaOAc, pH 5.2, 50 mM NiCl2, and 10 mM NaCNBH3. The 
NaCNBH3 was added from a 200 mM aqueous stock solution. The reaction was 
incubated at 37 °C for 14 h, and separated by 8% PAGE. 
3.4.4 Deoxyribozyme activity assays 
The 3′-dialdehyde-terminated capture oligonucleotide was prepared from 5′-
GGATAATACGACTCACTAT(rA)-3′ by oxidation of 20–5000 pmol of oligonucleotide in 20–
50 µL of 100 mM HEPES, pH 7.5, and 10 mM NaIO4 at room temperature for 1 h 
followed by ethanol precipitation. 
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The general assay procedure for each deoxyribozyme was as follows. A 10 µL 
sample containing 1 pmol of 3′-32P-radiolabeled RNA substrate, 10 pmol of 
deoxyribozyme, and 20 pmol of capture oligonucleotide was annealed in 5 mM HEPES, 
pH 7.5, 15 mM NaCl, and 0.1 mM EDTA by heating at 95 °C for 1 min and cooling on 
ice for 5 min. The reductive amination reaction was initiated by bringing the sample to 20 
µL total volume containing 100 mM NaOAc, pH 5.2, 50 mM NiCl2, and 10 mM 
NaCNBH3 and incubating at 37 °C. The NaCNBH3 was added from a 200 mM aqueous 
stock solution. At appropriate times, 2 µL aliquots were quenched with 6 µL of stop 
solution (80% formamide, 1 × TBE [89 mM each Tris and boric acid, 2 mM EDTA, pH 
8.3], 50 mM EDTA, and 0.025% each bromophenol blue and xylene cyanol). Before 
PAGE, to each sample was added 100 pmol of a decoy oligonucleotide, which was a 60-
mer complementary to the 40 nt catalytic region of the deoxyribozyme (to displace 
deoxyribozyme from substrate and product). Samples were separated by 20% PAGE and 
quantified with a PhosphorImager. kobs values were obtained by fitting the yield versus 
time data directly to first-order kinetics. 
3.4.5 DNA-catalyzed reductive amination products preparation 
To generate the reductive amination product for MS analysis, reactions were 
performed on a preparative scale. First, a 5′-hydroxyl RNA was phosphorylated with T4 
PNK, precipitated by ethanol, and desalted with a 3000 MWCO Amicon column. The 
extra desalting step using an Amicon column was found to be essential for the preparative 
scale reaction. Significant precipitation was observed in the reductive amination reaction 
when the Amicon desalting step was omitted.  
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To prepare the reductive amination product on a preparative scale, two reactions were 
performed for each individual deoxyribozyme. In each reaction, 1 nmol of 5′-
phosphorylated RNA, and 1.2 nmol of capture oligonucleotide, and 800 pmol of 
deoxyribozyme were annealed in 5 mM HEPES, pH 7.5, 15 mM NaCl, and 0.1 mM 
EDTA to a 30 µL sample by heating at 95 °C for 1 min and cooling on ice for 5 min. The 
reductive amination reaction was initiated by bringing the sample to 40 µL total volume 
containing 100 mM NaOAc, pH 5.2, 50 mM NiCl2, and 10 mM NaCNBH3 and 
incubating at 37 °C for overnight. The NaCNBH3 was added from a 200 mM aqueous 
stock solution. The reactions were desalted by ethanol precipitation and purified by 20% 
PAGE. 
3.4.6 DNase and RNAseT1 treatments  
 A 900 pmol portion of the 8QA124 reductive amination product was treated with 10 U  
of RQ1 RNase-free DNase (Promega) in 40 mM Tris, pH 8.0, 10 mM MgSO4, and 1 mM 
CaCl2 in 100 µL total volume at 37 °C for 14 h. The sample was extracted with 
phenol/chloroform, precipitated with ethanol, and separated by 20% PAGE. Three 
predominant bands were observed; the middle of these three was excised from the gel, 
extracted with TEN, and precipitated with ethanol. This DNase-digested product was 
treated with 20 U of RNase T1 (Ambion) in 50 mM Tris, pH 7.5, and 2 mM EDTA in 40 
µL total volume at 37 °C for 14 h. The sample was concentrated to 10 µL by SpeedVac, 
desalted by C18 ZipTip, and analyzed by MALDI mass spectrometry, revealing its 
identity as the pentamer 5′-pATrA–GGp-3′, where the new reductive amination linkage is 
between the rA and the G (calcd. 1735.2, found 1733.6, ∆ = –0.09%). MS/MS analysis 
was performed using an UltrafleXtreme TOF/TOF mass spectrometer (Bruker). 
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Chapter 4: Optimization of Click Chemistry Incubation Conditions for 
Direct Free Peptide Selection 
4.1 Introduction 
Chapter 2 and 3 describe our various selection efforts to achieve DNA-catalyzed 
covalent modification of a short peptide. In chapter 3, the selection effort with an 
additional reductive amination step was originally intended to select for free peptide 
activity; however, the selection effort gave rise to an unexpected DNA-catalyzed 
reductive amination that involves the exocyclic amino group of G1.1 Therefore, in this 
chapter, an alternative strategy was sought to avoid undesired side reactions in the 
capture step. The bioorthogonal Cu(I)-catalyzed Azide-Alkyne Cycloaddition2-3 
(CuAAC), the most commonly known example of click chemistry, has been widely 
developed for use in organic syntheses and bioconjugation reactions.3-8 CuAAC provides 
an excellent option for the capture step as CuAAC is highly specific to the alkyne and the 
azide functional groups. In addition, templated click reactions that involved 
oligonucleotide substrates have been reported.9-10 In this chapter, the optimization of 
CuAAC for direct selection using an azido-modified peptide is reported.  
4.2 Results and Discussion 
4.2.1 In vitro selection design 
We designed a two-stage strategy to seek DNA-catalyzed free peptide reactivity, 
which is shown in Fig. 4.1. During the selection step, deoxyribozymes append an azido 
bearing-peptide to themselves via reaction between the nucleophilic amino acid side 
chain with the 5′-triphosphate of the RNA. In the capture step, a capture oligonucleotide 
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that terminates with a 3′-alkyne reacts with the azido-bearing selection product via 
CuAAC reaction, forming a stable triazole linkage joining the capture oligonucleotide to 
the selection product. The capture step leads to a substantial gel-shift of the selection 
product which allows the separation of the selection product by PAGE.  
 
Figure 4.1 A two-stage design aims to select for DNA-catalyzed free peptide reactivity. The 
selection step allows deoxyribozymes append themselves to the peptide in which the N-
terminal is tethered to an azido propyl group via an amide linkage. The capture step 
employs CuAAC reaction between the azido-bearing peptide and a 3′-alkyne capture 
oligonucleotide, resulting in a gel-shift product which can be readily separated by PAGE. 
 
4.2.2 Click chemistry capture step optimization 
CuAAC capture step optimization in a trimolecular format. To ensure an efficient 
capture step, we sought the incubation conditions for the CuAAC reaction. The Cu(I) 
catalyst was prepared in situ from Cu(II) sulfate using sodium ascorbate as the reducing 
agent. In CuAAC reaction, severe degradation of oligonucleotide was observed.10 
Therefore, a minimum 5-fold excess of an aqueous Cu(I) stabilizing ligand tris(3-
hydroxypropyltriazolylmethyl)amine (THPTA) to the CuSO4 should be employed.10 We 
examined the optimal ratio of CuSO4: THPTA: sodium ascorbate as well as the optimal 
concentration for each key reactant in the capture step. It was previously reported10 that a 
final concentrations of 0.2 mM CuSO4, 1.38 mM THPTA, and 2 mM sodium ascorbate 
(1:7:10 CuSO4:THPTA:sodium ascorbate) were used in a CuAAC reaction between a 3′-
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azido modified oligonucleotide and an oligonucleotide with an alkyne at its 5′-end in a 
splinted fashion. To optimize the capture step, we first covalently ligated azido modified 
AYA to the RNA substrate via 15MZ36-catalyzed ligation between the Tyr of the azido 
modified AYA and the 5′-triphosphate RNA (see Materials and Methods). We performed 
CuAAC optimization in a trimolecular format, in which the azido modified AYA-RNA 
substrate was not covalently linked to the DNA pool. From the initial assay using a final 
concentrations of 0.4 mM CuSO4, 2.8 mM THPTA, and 4.0 mM sodium ascorbate in the 
CuAAC reaction, 73% of product was formed in 30 min (Fig. 4.2, condition C). 
 
Figure 4.2 Assays of azido modified AYA-RNA with the alkyne capture oligonucleotide and 
various concentrations of THPTA, sodium ascorbate and CuSO4. Condition B, highlighted 
by an asterisk, was a particular reaction condition that has been reported.4b The 3′-32P- 
radiolabeled azido modified AYA-RNA, the alkyne capture oligonucleotide, and the splint 
oligonucleotide were incubated in 50 mM HEPES, pH 7.5, 150 mM NaCl, followed by 
sequential addition of THPTA, sodium ascorbate, and CuSO4. Each of the latter three was 
prepared as 10× stock solutions. The reaction was incubated at 37°C. Time points were 
taken at 30 s, 30 min, 2 h, 4 h, 20 h.  
 
Having established a reliable capture step in a trimolecular format, we examined the 
CuAAC chemistry in cis, in which the DNA pool was covalently ligated to the azido 
modified-AYA-RNA substrate (see Materials and Methods for preparation). In order to 
mimic the selection conditions, we first incubated the internally radiolabeled azido 
modified-AYA-RNA-DNA pool substrate with 60 pmol of RNA-DNA pool in pH 7.5 
HEPES with 20 mM Mn2+ and 40 mM Mg2+, followed by ethanol precipitation. [Note: in 
a regular selection round, we estimated an upper limit of 20 pmol RNA-DNA pool was 
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present. 60 pmol of RNA-DNA pool was assayed in this optimization step as 200 pmol of 
RNA-DNA pool was used in the selection initiation round. We reasoned that a 60 pmol 
of the RNA-DNA pool (3-fold less than the initial round, 3-fold in excess of a regular 
round of selection) should be a good choice for the optimization.] After ethanol 
precipitation, the azido modified-AYA-RNA-DNA pool substrate was incubated in the 
optimized CuAAC condition which was described previously in the trimolecular format 
assay. To ensure the observed gel-shifted product was due to the Cu(I) catalyzed reaction, 
a negative control was performed by omitting CuSO4. Indeed, complete suppression of 
product formation was observed when CuSO4 was omitted. Also, THPTA was found to 
be necessary to minimize oligonucleotide degradation. We have established a capture 
step using CuAAC, in which ~50% of product was observed in 2 h (Fig. 4.3).  
 
Figure 4.3 Assays of azido modified AYA-RNA-DNA pool with the alkyne capture 
oligonucleotide in selection conditions. 32P-radiolabeled Azido modified AYA-RNA-DNA 
pool, 60 pmol RNA-DNA pool, 150 pmol of alkyne capture oligonucleotide, and 50 pmol of 
splint were incubated in 50 mM HEPES, pH 7.5, 150 mM NaCl, followed by sequential 
addition of THPTA, sodium ascorbate, and CuSO4 to a final volume of 20 µL. Each of the 
latter three was prepared as 10× stock solutions. A final concentrations of 0.4 mM CuSO4, 
2.8 mM THPTA, and 4.0 mM sodium ascorbate were used in the reaction. The reaction was 
incubated at 37°C. Time points were taken at 30 s, 30 min, 1 h, 2 h, and 18 h.  
 
4.3 Summary 
In this chapter, a new two-stage in vitro selection method to identify deoxyribozymes 
that catalyze peptide covalent modifications was developed. The novel in vitro selection 
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method involved the key selection step, followed by a capture step that employs a 
bioorthogonal CuAAC reaction. The newly developed capture step should be amenable to 
large peptides that are modified with an azide handle. 
4.4 Materials and Methods 
4.4.1 3′-Alkyne-modified capture oligonucleotide, splint, and helper 
oligonucleotides 
The 3′-alkyne-modified DNA was prepared by using the 3′-alkyne serinol CPG (Glen 
Research) using an ABI 394 DNA solid-phase synthesizer. RNA oligonucleotides were 
prepared by in vitro transcription using T7 RNA polymerase. 
3′-Alkyne:  5′-GCCGCATCAGACAGCG-3′Alkyne  
Splint:  5′-TTCGCCGTCGCCATCTCTTCCCGCTGTCTGATGCGGC-3′  
RNA:   5′-ggaagagauggcgacgg-3′  
Sel. Helper: 5’-AACAACAACAACAACAACAACGGATAATACGACTCACTAT-3’  
15MZ36 Helper: 5’-GGATAATACGACTCACTAT-3’  
 118 
4.4.2 Azido modified peptide preparation 
 
Scheme 4.1 Solid phase preparation of azido modified AYA. The last coupling and the deprotection step 
are illustrated. 
 
The azido modified AYA peptide was prepared by 0.2 mmol-scale Fmoc solid-phase 
peptide synthesis with Rink amide resin. Standard procedures (as described in chapter 2) 
were performed. For the last coupling (Scheme 4.1), 3-azidopropanoic acid (1 mmol, 5 
eq.) was activated by HATU coupling reagent (0.98 mmol, 4.9 eq) and DIPEA (2 mmol, 
10 eq) in 5 mL of DMF for 30 min before adding to the resin. The reaction was stirred 
under nitrogen at room temperature overnight. A Kaiser test was performed. The peptide 
was cleaved off the resins by TFA, triturated with ether, dried, and purified by HPLC. 
ESI-Mass calcd [M+H]+: 420.44; found:420.40. 
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Preparation of 3-azidopropanoic acid.  
 
Scheme 4.2 3-azidopropanoic acid preparation. 
Caution: Workup of reaction involving inorganic azide should avoid acid, because 
HN3 is volatile, explosive and toxic. Do not use halogenated solvents for reactions that 
involve inorganic azides. Halogenated solvent such as methylene chloride and 
chloroform could result in the formation of potentially explosive diazidomethane.11 
The 3-azidopropanoic acid was prepared according to the published procedure 
(Scheme 4.2).12 3-Bromoproanoic acid was dried under vacuum for 20 min before use. 
Into a 50 mL round-bottom flask, 2.7 g of 3-bromopropanoic acid (17.7 mmol, 1 eq.) was 
dissolved in 10 mL of anhydrous DMF. The solution was stirred at room temperature 
under argon. Sodium azide (3.48 g, 53.5 mmol, 3 eq.) was slowly added to the solution. 
The sodium azide was not soluble in DMF. The mixture was heated to 60 °C in an oil 
bath with a condenser for 48 h. A ESI mass spectrometry was taken with the crude 
compound and the desired product mass was observed. The reaction was stopped by 
diluting the reaction with 150 mL of acetonitrile, and filtering by suction filtration to 
remove excess sodium azide. The solution was concentrated by a rotary evaporator at 
room temperature behind a blast shield. Low res. ESI [M–H]– cacld: 114.09, found: 
114.20. 
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4.4.3 Aqueous Cu(I) ligand tris(3-hydroxypropyltriazolylmethyl)amine (THPTA) 
preparation  
 
Scheme 4.3 Aqueous Cu(I) ligand tris(3-hydroxypropyltriazolylmethyl)amine (THPTA) preparation. 
 
The aqueous Cu(I) THPTA ligand was prepared according to published procedures in 
the supportive information in ref (8) (Scheme 4.3). Note that the starting material, cuprous 
acetate, should not be green in color.  The green color indicates a significant oxidation to 
Cu(II) has occurred.  
3-azido-1-propanol preparation. 4 g of 3-bromo-1-propanol (28.8 mmol, 1 eq.) was 
dissolved in 30 mL of water in a round-botton flask at room temperature. Sodium azide 
(3.74 g, 57.6 mmol, 2 eq.) was added to the round-botton flask, followed by refluxing at 
90 °C for 20 h behind a blast shield. The reaction was cooled to room temperature. The 
reaction was extracted with 150 mL (3 × 50 mL) acetonitrile. The combined organic 
layers were dried over MgSO4 and concentrated by rotary evaporation behind the blast 
shield at room temperature to pale yellow oil (2.5 g). Storage of the concentrated 3-azido-
1-propanol oil should be avoided.  
THPTA ligand preparation. To a stirred solution of 3-azido-1-propanol (2.5g, 27.7 
mmol, 3.7 eq) and tripropargylamine (0.97g, 7.4 mmol, 1 eq.) in 25 mL THF, cuprous 
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acetate (18.2 mg, 0.15 mmol, 0.02 eq) was added under argon. The resulting solution was 
refluxed overnight. The mixture was concentrated and stirred with Cuprisorb resin (0.04 
g) to remove the copper ions. The solution was filtered and concentrated to yellow oil. 
 
1H NMR (500 MHz, DMSO-d6): δ 8.03 (s, 3H), 4.68 (t, J = 4.95 Hz, 3H), 4.41 (t, J = 
7.08 Hz, 3H), 3.61 (s, 6H), 3.40 (m, 6H), δ 1.96 (s, 6H) ppm. 
 
4.4.4 Preparation of azido modified AYA-RNA  
Azido modified AYA-RNA product was prepared both on radiolabeled and 
preparative scale. For radiolabeled-scale preparation. 1 pmol of 3′-32P-5′- triphosphate of 
RNA substrate, 10 pmol of 15MZ36, and 20 pmol of 15MZ36 helper oligonucleotide 
were annealed in 5 mM HEPES, pH 7.5, 15 mM NaCl, and 0.1 mM EDTA by heating at 
95 °C for 1 min and cooling on ice for 5 min. 0.4 µL of azido modified AYA (from 50 
mM stock solution in DMF) was added. The ligation reaction was initiated by addition of 
stock solutions to a final volume of 20 µL containing 50 mM HEPES, pH 7.5, 150 mM 
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NaCl, 2 mM KCl, 40 mM MgCl2, and 20 mM MnCl2. Final concentrations were 50 nM 
R, 0.5 µM E, 1 µM helper oligonucleotide, and 1 mM tripeptide substrate 
(1:10:20:20,000 R:E:helper:tripeptide). The reaction was incubated at 37 °C for 24 h, and 
purified on a 20 % PAGE (Fig. 4.4). The excised azido modified AYA-RNA product was 
used for the capture step optimization. 
 
Figure 4.4 3′-32P Azido-AYA-RNA prepared by the 15MZ36 deoxyribozyme. 
 
Preparative-scale preparation. The procedures were similar to the radiolabeled-scale 
detailed above. 1 nmol of 5′-triphosphate RNA, 1 nmol of the DNA helper 
oligonucleotide, and 700 pmol of 15MZ36 were annealed in 5 mM HEPES, pH 7.5, 15 
mM NaCl, and 0.1 mM EDTA by heating at 95 °C for 1 min and cooling on ice for 5 min 
in 50 µL. 2 µL of of Azido modified AYA (from 50 mM stock solution in DMF) was 
added and the ligation reaction was initiated by addition of stock solutions to a final 
volume of 100 µL containing 50 mM HEPES, pH 7.5, 150 mM NaCl, 2 mM KCl, 40 mM 
MgCl2, and 20 mM MnCl2 and incubated at 37 °C for 48 h. The reaction was ethanol 
precipitated, and purified on a 20 % PAGE. MALDI-TOF [M–H]–calcd: 6089.9, found: 
6084.4, ∆: –0.090% (Fig. 4.5). The excised azido modified-AYA-RNA sample was 
further ligated to a 5′-32P- radiolabeled DNA pool for capture step optimization in cis. 
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Figure 4.5 MALDI-TOF mass analysis of azido modified-AYA-RNA prepared by the 15MZ36 
deoxyribozyme.  
 
4.4.5 In vitro selection procedure using CuAAC chemistry 
Selection step. In the key selection step during each round of selection, the PCR-
amplified deoxyribozyme pool and 50 pmol of helper oligonucleotide (complementary to 
the 3′-binding arm of the deoxyribozyme) were annealed in 14 µL with 5 mM HEPES, 
pH 7.5, 15 mM NaCl, and 0.1 mM EDTA by heating at 95 °C for 1 min and cooling on 
ice for 5 min. The sample was brought to a final volume of 20 µL containing 50 mM 
HEPES, pH 7.5, 150 mM NaCl, 2 mM KCl, 40 mM MgCl2, 20 mM MnCl2, and 1 mM 
Azido modified AYA tripeptide (added from 50 mM stock solution in DMF) and 
incubated at 37 °C for 14 h, followed by ethanol precipitation.  
Capture Step. To the selection product, 150 pmol of capture oligonucleotide and 50 
pmol of splint (complementary to the capture oligonucleotide, the RNA substrate and 4 nt 
of the 5′ end of the DNA pool) were added to a final volume of 20 µL containing 50 mM 
 124 
HEPES, pH 7.5, 150 mM NaCl, 2.8 mM THPTA, 4.0 mM sodium ascorbate, and 4 mM 
CuSO4·5H2O. The latter three components were added sequentially, i.e., THPTA, then 
sodium ascorbate, followed by CuSO4·5H2O. The reaction was incubated at 37 °C for 2 h 
and separated on 8 % PAGE. 
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